

REMARKS

Claims 1, 2, 4-7, 10, 14, 15, 18, and 27-32 are pending in the application, claims 3 and 19-26 having been newly canceled and claims 27-32 added. Claims 1, 2, 6 and 7 are amended. The Examiner withdrew claims 10 and 18 from consideration. Claims 1, 2, 4-7, 14, 15, and 27-32 are under examination.

Support for the amendments to claims 1, 2, 6 and 7 can be found, for example, in claim 3 (now canceled) and at page 3, lines 30-32; page 9, lines 18-20; page 10, lines 21-27; page 11, line 21 to page 12, line 14; and page 12, lines 30-36. Support for new claims 27-32 can be found, e.g., at page 3, lines 27, to page 4, line 6; page 6, lines 7-15; page 8, lines 5-6 and 32-35; and page 14, lines 30-32; and in the claims as originally filed. The indicated passages from the specification disclose that the screening methods can ultimately be used to generate a bispecific antibody (BsAb) or a multi-specific antibody with specificity for three or more antigens. As such a use would be recognized by one of ordinary skill in the art as inherently involving the steps specified in the various new claims, Applicants submit that no new matter has been added. Applicants further submit that, since the new claims are all method claims that are dependent on method claims 1, 2, 5 or 7, the new claims belong to the same restriction group as the latter claims and should be examined in the present case.

Claims 1-7 and 13-15 were rejected for lack of enablement under 35 USC § 112, paragraph 1. See pages 4-7 of the Office action. The Office action acknowledged that one prior ground for rejection, that the host cell used with the phage-based screening assay must be bacterial, was overcome by Applicants' prior amendment of the claims to require use of bacterial host cells. The second ground for the enablement rejection appears to be based on the Examiner's concern that the claimed screening assay would not work even in bacterial hosts. The Office action says at page 5,

The specification is enabling for using a host cell system compatible with a phage library being introduced into the host cell such as a bacterium which produces phage particles expressing an assembled antibody heavy and light chain on the particle surface after following the method steps.... The specification is not enabling for any host cell having the ability to "secrete" an antibody heavy chain much less where a bacterial host

cell secretes the first or second or third antibody heavy chain. The claims encompass any host cell a) having the ability to secrete an antibody heavy chain and b) capable of being infected with a phage particle library whereas the specification is only enabling for using phage particles to infect a bacterium where at most the resultant, selected phage particle library also expresses the heavy chain and light on the surface.

As Applicants understand it, the Examiner's position seems to be that a phage-based screening assay in bacteria that produces phage particles expressing an assembled antibody heavy and light chain on the phage particle surface would work, while a phage-based screening assay that involves secretion of a heavy chain by the bacterium would not work. If this interpretation of the Examiner's position is not what was intended, Applicants respectfully request clarification.

Applicants point out that phage-based antibody screening assays that involves association of separate heavy and light chains (or fragments thereof) on the surface of the phage generally require that both of the chains be secreted in the periplasmic space (one of the chains being fused to a phage protein that self-assembles with other phage proteins to form the phage particle and the second chain being expressed as a separate polypeptide that associates with the phage-anchored chain). This is illustrated by the Griffiths et al. reference (EMBO J 13:3245-3260, 1994) that was supposed to be submitted with the prior Response filed March 17, 2009. A copy of the Griffiths et al. reference is attached hereto as Exhibit A; Applicants sincerely apologize for neglecting to include it with the prior Response. Griffiths et al. describe a method of screening for two-chain antibody fragments (Fab fragments) using phage display in bacteria. See the abstract. In the Griffiths et al. scheme illustrated in Fig.2A, both the heavy chain fragment (VH+CH1) and the light chain fragment (C_κ) are encoded as separate polypeptides on a phage vector, with the light chain fragment linked to the phage gene III leader sequence and the heavy chain fragment linked to both the PelB leader sequence and the phage gene III polypeptide (see Fig. 2A). The heavy chain fragment would thus be secreted into the periplasmic space by the PelB leader sequence as a fusion protein linked to the phage gene III polypeptide. The light chain fragment is presumably secreted into the periplasmic space by the gene III leader sequence. Though Griffiths et al. does not specify where the association of the two fragments to form a Fab occurs, presumably it is in the periplasmic space where the phage structure

(containing the gene III protein) is assembled. Thus, Griffiths et al. provides evidence that a functional Fab fragment can form in the periplasmic space following expression and secretion of two antibody chain fragments, one being attached to a phage protein.

Furthermore, Kipriyanov (cited in the Office action) states at page 181, left column, that “bacterial systems are widely used for the production of antibody fragments such as Fab...” and “A rapid growth in the field of antibody engineering occurred after it was shown that functional antibody fragments could be secreted into the periplasmic space and even into the medium of *E. coli* by fusing a bacterial signal peptide to the antibody's N-terminus.” Furthermore, Kipriyanov says at page 190, “Periplasmic expression has permitted the functional testing of a wide variety of antibody fragments with different antigen binding specificities. The antibody fragments are usually correctly processed in the periplasm, they contain intramolecular disulfide bonds and are soluble.” Since the Examiner indicated at page 6 of the Office action that reliance on the teachings of Kipriyanov in this regard would require inclusion of a claim limitation regarding the use of a bacterial secretion signal sequence, Applicants have added such a limitation to the claims. Though Kipriyanov goes on to say that “high-level expression of a recombinant protein with a bacterial signal sequence in *E. coli* often results in the accumulation of insoluble antibody fragments after transport to the periplasm,” this particular problem is said to occur with “high-level” expression, as when large amounts of a given antibody are desired, and not the level of expression one would seek for “functional testing” (e.g., in a screening assay), as disclosed by Kipriyanov. Applicants believe that Kipriyanov is strong support for Applicants' position that the present claims are fully enabled.

The Office action also cites Zauderer et al., US 20080167193, in support of the rejection, referring in particular to passages at [0013] and [0016] of this reference. Zauderer et al., which touts antibody libraries expressed in eukaryotic cells, says of bacteriophage and bacterial libraries:

Many antigen binding regions, however, are difficult to assemble correctly as a fusion protein in bacterial cells. In addition, the protein will not undergo normal eukaryotic post-translational modifications. As a result, this method imposes a different selective filter on the antibody specificities that can be obtained... . Assays for expression in bacterial hosts are often impeded, however, because the protein may not be sufficiently

expressed in bacterial hosts, it may be expressed in the wrong conformation, and it may not be processed, and/or transported as it would in a eukaryotic system. Many of these problems have been encountered in attempts to produce immunoglobulin molecules in bacterial hosts. Zauderer et al., [0013] and [0016].

Regardless of whether the concerns stated by Zauderer et al. above are true, it remains a fact that bacteriophage display of antibody fragments has long been a standard technique in the field. See, for example, the many publications cited in Zauderer et al. at paragraph [0011]. Clearly the methods generally work and can be carried out successfully without undue experimentation. There is absolutely no reason to conclude that Zauderer et al.'s unsupported statements about "difficulties" and "problems" suddenly remove an otherwise standard technique from the skill set of those of ordinary skill in the art. Nor is there any reason to believe that Applicants' novel screening method would be any more difficult to carry out than the phage display techniques that are standard in the art.

Applicants submit that the presently claimed methods are fully enabled by the specification. Withdrawal of the rejection and allowance of the claims is respectfully requested.

Please apply the fee necessary for the three-month extension of time, as well as any other charges or credits, to deposit account 06-1050, referencing Attorney Docket No. 14875-0148US1.

Respectfully submitted,

Date: December 2, 2009 _____

/Janis K. Fraser/_____
Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
Customer No.: 26161
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

Isolation of high affinity human antibodies directly from large synthetic repertoires

Andrew D.Griffiths¹, Samuel C.Williams²,
Oliver Hartley¹, Ian M.Tomlinson¹, Peter
Waterhouse^{1,6}, William L.Crosby^{1,5}, Roland
E.Kontermann¹, Peter T.Jones¹, Nigel
M.Low², T.John Allison², Terence
D.Prospiero¹, Hennie R.Hoogenboom^{1,4},
Ahuva Nissim¹, Jonathan P.L.Cox^{1,7},
Jacqueline L.Harrison¹, Manuela Zaccolo³,
Ermanno Gherardi³ and Greg Winter^{1,2}

¹MRC Centre for Protein Engineering, ²MRC Laboratory of Molecular Biology and ³ICRF Cell Interactions Laboratory, MRC Centre, Hills Road, Cambridge CB2 2QH and ⁴Cambridge Antibody Technology Ltd, The Science Park, Melbourn, Cambridgeshire SG8 6EJ, UK

Present address: ⁵National Research Council of Canada, Plant Molecular Genetics, 110 Gymnasium Road, Saskatoon, Saskatchewan, Canada S7N-0W9, ⁶CSIRO Division of Plant Industry, GPO Box 1600, Canberra ACT 2601, Australia and ⁷University of Bath, School of Chemistry, Claverton Down, Bath BA2 7AY, UK

Communicated by G.Winter

Antibody fragments of moderate affinity ($\sim\mu\text{M}$) can be isolated from repertoires of $\sim 10^8$ immunoglobulin genes by phage display and rounds of selection with antigen, and the affinities improved by further rounds of mutation and selection. Here, as an alternative strategy, we attempted to isolate high affinity human antibodies directly from large repertoires. We first created highly diverse repertoires of heavy and light chains entirely *in vitro* from a bank of human V gene segments and then, by recombination of the repertoires in bacteria, generated a large (close to 6.5×10^{10}) synthetic repertoire of Fab fragments displayed on filamentous phage. From this repertoire we isolated Fab fragments which bound to a range of different antigens and haptens, and with affinities comparable with those of antibodies from a secondary immune response in mice (up to 4 nM). Although the VH-26 (DP-47) segment was the most commonly used segment in both artificial and natural repertoires, there were also major differences in the pattern of segment usage. Such comparisons may help dissect the contributions of biological mechanisms and structural features governing V gene usage *in vivo*.
Key words: high affinity/human antibodies/phage

Introduction

The display on the surface of filamentous bacteriophage (Smith, 1985) of antibody fragments (McCafferty *et al.*, 1990; Barbas *et al.*, 1991; Breitling *et al.*, 1991; Garrard *et al.*, 1991; Hoogenboom *et al.*, 1991) by fusion to a

minor coat protein of phage (pIII), and selection of the phage with antigen, has provided a powerful means of making antibodies of predefined binding specificity from V gene repertoires (for review see Winter *et al.*, 1994). Starting from repertoires derived from the V genes of an immune response, antibody fragments have been readily isolated with high affinity (Clackson *et al.*, 1991), and even with neutralizing activities against virus (Barbas *et al.*, 1992a,b).

The display and selection of antibody fragments on the surface of phage mimics immune selection (for review see Marks *et al.*, 1992a), and antibodies have also been isolated without immunization, from repertoires of V genes rearranged *in vivo* (Marks *et al.*, 1991) or *in vitro* (Hoogenboom and Winter, 1992). The same phage repertoire may be used to generate many different binding specificities, including those that are difficult to raise by immunization, for example against self-antigens (Griffiths *et al.*, 1993; Marks *et al.*, 1993) or proteins of the lumen of the endoplasmic reticulum (Nissim *et al.*, 1994). Antibodies from such 'single pot' libraries appear to be highly specific and have been used for 'on-line detection' of antigen in biosensors (M.Malmqvist, unpublished), and for Western blotting and epitope mapping (Nissim *et al.*, 1994). But the affinities were not high ($\sim\mu\text{M}$), as expected for primary repertoires of 10^7 – 10^8 clones.

It should also be possible to isolate high affinity antibodies (<10 nM) directly from primary repertoires of sufficiently large diversity and size (Perelson and Oster, 1979), but the size and diversity of repertoires required is not known. The size and 'shape' of natural repertoires is limited not only by the number of B-lymphocytes ($\sim 5 \times 10^8$ in mouse and $\sim 10^{12}$ in human), and the number of lymphocytes in each clone, but also by the processes of clonal deletion and anergy that lead to self tolerance (for review see Nossal, 1993).

Here we constructed a highly diverse combinatorial repertoire entirely *in vitro*, using V gene segments as building blocks. We used the vast majority of heavy and light chain segments used *in vivo* and encoded part, or all, of each CDR3 loop by random sequence. To make the repertoire as large as possible we infected bacteria harbouring a 'donor' heavy chain repertoire (on a plasmid) with an 'acceptor' light chain repertoire (on phage). The two chains were combined on the same (phage) replicon within the bacterium by Cre catalysed recombination at *loxP* sites. This process, termed 'combinatorial infection' (Waterhouse *et al.*, 1993), generates a large number of heavy and light chain combinations, potentially as large as the number of bacteria that have been infected. The repertoire was characterized by the properties of the selected Fab fragments.




Fig. 1. Construction of synthetic heavy and light chain repertoires. (A) The repertoire of heavy chains ($>10^8$ different clones) was built from 49 cloned V_H segments (Tomlinson *et al.*, 1992; Nissim *et al.*, 1994), with CDR3 loops of four to 12 residues of random sequence. (B) The repertoire of κ light chains (9×10^4 clones) was built from 26 cloned V_K segments (Cox *et al.*, 1994) with CDR3 loops of eight to 10 residues that included one, two or three residues of random sequence in all cases. DPK-4 is shown by way of an example. (C) The repertoire of λ light chains (7.4×10^5 clones) was built from 21 cloned V_λ segments (Williams and Winter, 1993), with CDR3 loops of eight to 13 residues that included zero, one, two, three, four or five residues of random sequence. DPL-12 is shown by way of example. CDR, complementarity determining region; FR, framework region. Neither the single segment of the V_K7 subgroup, nor the few segments from the V_λ families 4, 5 or 6, were included in the repertoire. Segments rarely used *in vivo*, for example light chain segments (DPK-2, -7, -10, -12, -17, -19, -20, -23 and -25) from the distal V_K locus (Cox *et al.*, 1994), were represented equally in the synthetic repertoire. Some of the V_H gene segments (DP-1, -12, -30, -39, -40, -44, -45 and -69) included in the repertoire are now known to be located on chromosomes 15 or 16, and therefore outside the functional locus (Tomlinson *et al.*, 1994).

Results

Repertoire size and diversity

Heavy and light chain repertoires were built from the majority of human V gene segments as described in Figure 1. The light chain repertoire was cloned into 'acceptor' fd phage (tetracycline resistant), with a 'dummy' heavy chain (Figure 2A), and the heavy chain repertoire into 'donor' plasmid (ampicillin resistant) (Figure 2B). The repertoires, $>10^8$ heavy chains and $>8 \times 10^5$ light chains, were combined by infection of *Escherichia coli* harbouring the donor heavy chains with fd phage carrying the light chains. If every heavy chain were paired with every light chain, this would generate a repertoire of $>8 \times 10^{13}$ antibodies. The culture was then co-infected with bacteriophage P1 (chloramphenicol resistant), which provides the Cre recombinase (Waterhouse *et al.*, 1993), leading to 6.5×10^{10} colonies resistant to ampicillin, tetracycline and chloramphenicol (for summary, see Table I). After growth of the cultures, the fd phage were used to infect *E. coli*. Twenty-eight per cent of the acceptor phage were shown to have acquired a heavy chain from the donor vector (see




Fig. 2. Vectors. (A) The fd phage 'acceptor' vector fdDOG-2loxVkdcl. Light chain genes (V_K-C_K and $V_\lambda-C_\lambda$) are cloned into this vector as *ApaLI*-*AscI* fragments. (B) The plasmid 'donor' vector pUC19-2loxVHdel. Heavy chain variable region genes (V_H genes) are cloned into this vector as *NcoI*-*XhoI* fragments. (C) The phagemid expression vector pUC119His6mycXba. Heavy and light chain genes encoding Fabs are cloned into this vector as *XbaI*-*NotI* fragments. Other features are marked as follows: sequences encoding Lg3, gene III leader sequence; LpelB, pelB leader sequence; Ck, human kappa light chain constant region; VH, heavy chain variable region; CH1, first heavy chain constant domain (human C μ 1 in fdDOG-2loxVkdcl and human C γ 1 in pUC19-2loxVHdel); α TNF-H, the V_H gene of the mouse anti-TNF α antibody mAb32 (Rathjen *et al.*, 1992) linked to a human C μ 1 constant domain gene; gIII, fd phage gene III; *loxP* wt, wild-type *loxP* site (Hoess *et al.*, 1982); *loxP* 511, a mutant *loxP* site with a single point mutation (Hoess *et al.*, 1986); myc, peptide from c-myc recognized by the monoclonal antibody 9E10 (Munro and Pelham, 1986); His6, six histidines.

Materials and methods). As there are multiple copies of plasmid and phage replicons in each bacterial cell when Cre recombinase is delivered by phage P1 infection and at least 60 phage are produced per bacterium after overnight growth, we believe that each bacterium should yield at least one phage containing the heavy chain from the donor vector and therefore we estimate that the repertoire contained close to 6.5×10^{10} different phage antibodies, with up to 60 copies of each.

Specificity of selected antibodies

The repertoire of phage was selected with a range of antigens, leading to isolation of binding specificities, as

Table I. Determination of repertoire size

Sample Point	Total no. of colony forming units ($\times 10^{10}$)						Significance
	No antibiotic	amp ^R	tet ^R	chlor ^R	amp ^R + tet ^R	amp ^R + tet ^R + chlor ^R	
1		0.17					size of pUC19-2loxVHlib inoculum from frozen stock;
2	3.4	2.3					size of pUC19-2loxVHlib inoculum from overnight culture;
3	65 (λ)		10 (λ)		19 (λ)		no. of <i>E. coli</i> containing pUC19-2loxVHlib infected with fdDOG-2loxV λ lib;
	73 (κ)		11 (κ)		8.0 (κ)		no. of <i>E. coli</i> containing pUC19-2loxVHlib infected with fdDOG-2loxV κ lib;
4	9.5 (λ)	22 (λ)	4.5 (λ)	6.0 (λ)	3.0 (λ)	2.0 (λ)	no. of <i>E. coli</i> containing pUC and fdDOG replicons co-infected with phage P1;
	29 (κ)	28 (κ)	7.5 (κ)	28 (κ)	3.0 (κ)	4.5 (κ)	no. of <i>E. coli</i> containing pUC and fdDOG replicons co-infected with phage P1;
5							titre of fdDOG phage (t.u.) immediately after P1 infection and centrifugation;
6	31 (λ)					16 (λ)	no. of viable <i>E. coli</i> containing pUC, fdDOG and P1 replicons after 24 h;
	35 (κ)					9.5 (κ)	no. of viable <i>E. coli</i> containing pUC, fdDOG and P1 replicons after 24 h;
7							titre of fdDOG phage (t.u.) after 24 h;

Sample point, see Materials and methods; amp^R, ampicillin resistant; tet^R, tetracycline resistant; chlor^R, chloramphenicol resistant.

summarized in Table II. The repertoire was selected on all antigens and haptens by panning on antigen coated immunotubes; for the haptens NIP and fluorescein, the phage were also captured with biotinylated NIP-BSA and FITC-BSA and streptavidin-coated paramagnetic beads. To follow the selection process, *E. coli* were infected with the eluted phage after each round, and the phage screened for binding to antigen by ELISA, either as a 'polyclonal' population or as phage clones. DNA encoding the Fab fragments was amplified using the polymerase chain reaction from the population of phage after two to four rounds of selection and recloned into plasmid (Figure 2C) for expression of soluble Fab fragments.

We focused on the characterization of Fab fragments with specificities against the hapten-BSA conjugates of NIP (3-iodo-4-hydroxy-5-nitrophenyl-acetate) and FITC (fluorescein 5-isothiocyanate), as it would allow comparisons with the natural immune response to both haptens in mice, and facilitate the measurement of binding affinities to the free haptens (by fluorescence quench titrations). The fragments against hapten-BSA were first screened for binding to the free hapten by competition with fluorescein or NIP-caproic acid (NIP-CAP), or for binding to BSA. Most of the Fab fragments bound to hapten-BSA, but some also bound to BSA, or to free hapten.

We also characterized Fab fragments against four antigens of the kringle-serine protease family—hepatocyte growth factor/scatter factor (HGF/SF), plasmin, urokinase-type plasminogen activator (u-PA), and tissue-type plasminogen activator (t-PA)—as members of a family of related proteins. Binding of 'polyclonal' phage was detected after three rounds of selection and proved to be specific, despite homologies between the members of this family (Figure 3). We also characterized Fab fragments against the mouse monoclonal antibody NQ11/7.22 (Griffiths *et al.*, 1984), as the binding could be mapped to the variable regions, to the Fc region and to the remaining portions of the monoclonal antibody (Table III).

Segment usage of selected heavy and light chains

The phage selected from the large (6.5×10^{10} clones) repertoire by binding to antigen were characterized by DNA sequencing. Many of the clones were different: 137

Table II. Binding specificities isolated from the library

Haptens

3-iodo-4-hydroxy-5-nitrophenyl-acetate (NIP)
Fluorescein
2-phenyloxazol-5-one (phOx)
N-(Carboxymethyl)-4-[(*p*-nitrobenzyloxylphosphoryl)-butyramide]
N-(2-hydroxy-3-(4-nitrophenyl))-propyl-L-prolyl-glycine

Foreign antigens

Serum albumin (BSA) (bovine)
Tubulin (bovine)
Calmodulin (bovine)
Hepatocyte growth factor/scatter factor (HGF/SF) (murine)
Monoclonal antibody NQ11/7.22 (murine)
FixL (*Bradyrhizobium japonicum*)
Acetolactate synthase (ALS) (*Brassica napus*)
Lol pII (*Lolium perenne*)
Gene product of CDC4 (*Schizosaccharomyces pombe*)
Gene product of CDC8 (*Schizosaccharomyces pombe*)
Maltose binding protein (*E. coli*)
gp120 (HIV-1)
gp11 (T4 phage)
gp9 (T4 phage)

Human antigens

Tumour necrosis factor α (TNF α)
Thyroglobulin
High affinity IgE receptor (Fc ϵ RI)
Tissue-type plasminogen activator (t-PA)
Urokinase-type plasminogen activator (u-PA)
Plasmin
Carcinoembryonic antigen (CEA)
c-erb B2
Tau40
Elongation factor 1 α (EF-1 α)
Calreticulin
Calnexin
Ferritin light chain
Factor VIII
U1 snRNA
U1A protein
U1C protein

unique antigen-binding Fab fragments (with differing light or heavy chain protein sequences) were identified from a total of 215 clones sequenced (Table III). A range of V gene segments was seen: 17 of the 49 V_H segments, 10 of the 26 V_K segments and nine of the 21 V_L segments




Fig. 3. Specificity of polyclonal phage against kringle serine protease family. 'Polyclonal' phage after one, two, three and four rounds of selection on either HGF/SF, plasmin, u-PA or t-PA, were assayed by ELISA for binding to the other members of the family, and to BSA.

(see Figure 4). Each of the major heavy and light chain families were represented (Chuchana *et al.*, 1990; Kabat *et al.*, 1991; Williams and Winter, 1993), but not all the minor families. Thus V_H segments were seen from families 1, 3, 4 and 5, but not 2 and 6; V_K segments from subgroups 1, 2, 3 and 4, but not from 6; and V_λ segments from families 1, 2, 3, 7 and 8, but not 9. The heavy chain V_H segment DP-45 (included in the repertoire, but located on chromosome 16 outside the major locus on chromosome 14) was found in two Fab fragments (Table III and Figure 4A) binding to NIP-BSA.

Some V gene segments (V_H segments DP-7, DP-38, DP-47 and DP-67; V_K segment DPK-15; and V_λ segment DPL-3) were seen frequently in the synthetic chains: of these only the V_H segment DP-47 is common in natural antibodies. Conversely, some segments (like V_H segments DP-63 and DP-71; V_K segments DPK-1 and DPK-21; and V_λ segments DPL-5 and DPL-23) that are common in natural antibodies were not seen in the synthetic chains (Figure 4). Thus, except for DP-47, the pattern of usage of the segments from the synthetic repertoire, summed

Table III. CDR3 sequences and germline V gene segments from antigen-binding clones

Antigen ^a	Clone	Heavy chains ^b			Light chains ^c			Selection method ^d	Round ^e	No. of copies ^f
		Family	Segment	CDR3 ^g	Family	Segment	CDR3 ^g			
NIP-BSA	G09	VH3	DP-38	AGTL	Vλ1	DPL-3	AAWDDSLV	M	4	1
NIP-BSA	E01	VH3	DP-38	AGTL	Vκ2	DPK-12	MQSIQLPT	M	3/4	2
NIP-BSA	G10	VH3	DP-38	AGTL	Vκ2	DPK-12	MQSIQLPAT	M	4	1
NIP-BSA	G04	VH3	DP-38	AGTL	Vλ1	DPL-3	AAWDDGLSLV	M	4	1
NIP-BSA	H08	VH3	DP-38	AGTL	Vλ1	DPL-3	AAWDDSLSGV	M	4	1
NIP-BSA	G07	VH3	DP-38	AGTL	Vλ3	DPL-16	NSRDSSGSRV	M	4	1
NIP-BSA	C09	VH3	DP-38	GGKD	Vλ7	DPL-18	LLYYGGAYV	Im	4	1
NIP-BSA	F03	VH1	DP-10	GGRL	Vλ3	DPL-16	NSRDSSGSRV	M	3	1
NIP-BSA	E07	VH3	DP-38	GGTQ	Vλ1	DPL-3	AAWDDSLV	M	3	1
NIP-BSA	H05	VH3	DP-38	GGTQ	Vλ1	DPL-3	AAWDDSLPYV	M	4	1
NIP-BSA	H03	VH3	DP-38	HGQH	Vλ1	DPL-3	AAWDDSLCPEFV	M	4	1
NIP-BSA	H01	VH3	DP-38	KGSE	Vλ1	DPL-3	AAWDDSLAWFV	M	4	1
NIP-BSA	A12	VH3	DP-47	KGWS	Vλ1	DPL-4	LAWDTSPRWV	Im	3	1
NIP-BSA	A10	VH3	DP-47	KGWS	Vλ3	DPL-16	TAWDDSLAVV	Im	3	1
NIP-BSA	D08	VH3	DP-47	KGWS	Vκ3	DPK-22	NSRDSSGNHRV	Im	4	1
NIP-BSA	G02	VH3	DP-49	LGKA	Vλ1	DPL-3	QYQSSQRT	M	4	1
NIP-BSA	E06	VH3	DP-38	NGYF	Vλ1	DPL-3	AAWDDSLRLV	M	3	1
NIP-BSA	D03	VH3	DP-49	PRGY	Vλ1	DPL-3	AAWDDSLRLV	Im	4	1
NIP-BSA	B02	VH3	DP-46	MYMRS	Vκ2	DPK-18	MQGTHWRPT	Im	3	1
NIP-BSA	E02	VH3	DP-46	MYRSV	Vκ2	DPK-18	MQGKHWPPT	M	3	1
NIP-BSA	A06	VH3	DP-42	NGGHV	Vλ1	DPL-3	AAWDDSLGF	Im	3	1
NIP-BSA	D05	VH3	DP-47	PAGSR	Vκ2	DPK-18	MQGTHRRAT	Im	4	1
NIP-BSA	A04	VH3	DP-38	PATRS	Vκ2	DPK-15	MQUALQTPPT	Im	3	1
NIP-BSA	F06	VH3	DP-47	PFATF	Vκ2	DPK-18	MRGTHRRAT	M	3	1
NIP-BSA	E08	VH3	DP-51	PFLAH	Vκ2	DPK-18	MQGTHWHPT	M	3	1
NIP-BSA	C05	VH3	DP-32	PLGAH	Vκ2	DPK-15	MQUALQSPT	Im	4	1
NIP-BSA	E12	VH3	DP-47	PMRGV	Vκ2	DPK-18	MQGTHRRAT	M	3	1
NIP-BSA	E05	VH3	DP-38	PNGDQ	Vλ1	DPL-3	AAWDDSLAFV	M	3	1
NIP-BSA	E04	VH3	DP-38	POTRR	Vκ2	DPK-15	MQUALQTPPT	M	3	1
NIP-BSA	A08	VH3	DP-47	PRLPR	Vκ1	DPK-9	QQSYSTRT	Im	3	1
NIP-BSA	E10	VH5	DP-73	PSGNV	Vκ2	DPK-19	MQGTHWPPT	M	3	1
NIP-BSA	A05	VH1	DP-25	QGLRN	Vκ2	DPK-15	MQUALQTPPT	Im	3	1
NIP-BSA	D06	VH3	DP-47	RGHKA	Vκ2	DPK-18	MQGTHWPAT	Im	4	1
NIP-BSA	D02	VH3	DP-51	SRGDS	Vλ1	DPL-3	AAWDDSLRSV	Im	4	1
NIP-BSA	F01	VH3	DP-47	TFSPQ	Vκ2	DPK-18	MQGTHRRAT	M	3	1
NIP-BSA	B03	VH3	DP-47	SFRRLN	Vλ1	DPL-3	AAWDDSLLV	Im	3	1
NIP-BSA	A11	VH3	DP-58	SFRRLN	Vκ3	DPL-16	DSWDNSLVSPV	Im	3	1
NIP-BSA	C04	VH3	DP-38	PGYRGTR	Vκ2	DPK-15	MQUALQSPT	Im	4	2
NIP-BSA	D07	VH3	DP-38	PGYRGTR	Vκ2	DPK-12	MQSIQLPT	Im	4	1
NIP-BSA	D01	VH3	DP-38	PGYRGTR	Vκ2	DPK-15	MQUALQSPAT	Im	4	1
NIP-BSA	C10	VH3	DP-38	PGYRGTR	Vλ1	DPL-3	AAWDDSLSAYV	Im	4	1
NIP-BSA	C11	VH3	DP-38	PGYRGTR	Vλ3	DPL-16	NSRDSSGRVNV	M	3	1
NIP-BSA	F04	VH3	DP-45	RAINGQR	Vκ2	DPK-15	MQUALRTRT	Im	3	1
NIP-BSA	B04	VH3	DP-47	RRGSTRY	Vλ3	DPL-16	NSRDSSGSRV	M	3	1
NIP-BSA	F05	VH3	DP-38	VNSRFAT	Vκ2	DPK-19	MQGTHWPPT	M	3	1
NIP-BSA	E11	VH4	DP-67	IKFRSSSI	Vλ1	DPL-3	AAWDDSLPYV	M	4	1
NIP-BSA	H06	VH4	DP-67	SFAKAFDY						

Table III. Continued

Antigen ^a	Clone	Heavy chains ^b			Light chains ^c			Selection method ^d	Round ^e	No. of copies ^f
		Family	Segment	CDR3 ^g	Family	Segment	CDR3 ^g			
NIP-BSA	E09	VH4	DP-67	SFAKAFDY	Vλ3	DPL-16	NSRDSSGSVRV	M	3	1
NIP-BSA	C02	VH1	DP-7	SKRTSFDY	Vκ2	DPK-18	MQGTHWHPT	Im	4	1
NIP-BSA	G08	VH3	DP-47	SLFSKFDY	Vλ3	DPL-16	NSRDSSGSVRV	M	4	1
NIP-BSA	A07	VH3	DP-47	SVLSLFDY	Vλ1	DPL-3	AAWDDSLFYPV	Im	3	1
NIP-BSA	C03	VH3	DP-45	SYMGRMRN	Vλ3	DPL-16	NSRDSSGNHRV	Im	4	1
NIP-BSA	A02	VH3	DP-42	HRRAYYMI	Vκ2	DPK-18	MQGTHWPVT	Im	3	1
NIP-BSA	A09	VH4	DP-67	IGKLSQPTS	Vκ2	DPK-18	MQGTHWRPT	Im	3	1
NIP-BSA	E03	VH3	DP-47	RSQVRMLID	Vκ2	DPK-18	MQGTHWRT	M	3	1
NIP-BSA	A03	VH3	DP-42	HLRWASGGPR	Vκ2	DPK-18	MQGTHWRT	Im	3	1
NIP-BSA	G11	VH3	DP-47	PLNSKKNNTTQ	Vλ1	DPL-3	AAWDDSLFYV	M	4	1
NIP-BSA	C12	VH3	DP-49	GRTWSPSLPPLR	Vκ2	DPK-12	MQSIQLPLT	Im	4	1
NQ11 (Fc)	NML7	VH3	DP-47	KWGG	Vλ1	DPL-2	AAWDDSLGSGV	Im	2	1
NQ11 (Fc)	NML9	VH1	DP-14	GTGLDG	Vλ2	DPL-10	CSYAGSSYV	Im	2	1
NQ11 (Fc)	NML8	VH3	DP-47	KFGNNM	Vλ3	DPK-23	QQDYNNLT	Im	2	1
NQ11 (Fv)	NML1	VH3	DP-47	ASSPFVLQ	Vλ8	DPL-21	VLYMGSGSAV	Im	2/3/4	25
NQ11	NML3	VH1	DP-7/3 ^h	YKLSFDY	Vκ2	DPK-13	MQRIEFPNT	Im	2	1
NQ11	NML5	VH1	DP-10	AANYSKAHI	Vλ1	DPL-2	AAWDDSLACAV	Im	2/3	4
NQ11 (Fv)	NML2	VH3	DP-47	RSWDGGMVD	Vκ1	DPK-5	QQANSFRT	Im	2	1
NQ11 (Fc)	NML11	VH3	DP-3	SKLWVTFDY	Vλ1	DPL-8/2 ^h	AAWDDSLSRPV	Im	3	1
NQ11 (Fc)	NML6	VH3	DP-3	SKLWVTFDY	Vλ1	DPL-2	AAWDDSLSRPV	Im	2/3/4	34
NQ11	NML4	VH3	DP-3	AKQSGVECLT	Vλ1	DPL-3	AAWDDSLYNV	Im	2	2
NQ11 (Fc)	NML10	VH3	DP-3	SKYPLAWTSL	Vλ1	DPL-2	AAWDDSLNRNV	Im	2	1
FITC-BSA	B01	VH3	DP-47	ALRR	Vκ2	DPK-15	MQVLQTRT	Im	3	1
FITC-BSA	B06	VH3	DP-47	GGRV	Vκ2	DPK-15	MQALQTRT	Im	3	1
FITC-BSA	A03	VH3	DP-47	IGQF	Vλ1	DPL-3	AAWDDSLAFV	Im	3/4	4
FITC-BSA	D10	VH3	DP-47	KAKT	Vκ2	DPK-15	MQALQTRT	Im	4	1
FITC-BSA	G06	VH3	DP-47	KSAI	Vκ2	DPK-15	MQALQTRT	M	4	1
FITC-BSA	H03	VH3	DP-47	KSRW	Vκ1	DPK-9	QQSYSTRM	M	4	1
FITC-BSA	D12	VH3	DP-47	KSTV	Vκ2	DPK-15	MQALRTRT	Im	4	1
FITC-BSA	A08	VH3	DP-47	LNRR	Vκ2	DPK-15	MQALQTRT	Im	3/4	4
FITC-BSA	D08	VH3	DP-47	RHGS	Vκ2	DPK-15	MQALRTRT	Im	4	1
FITC-BSA	G07	VH3	DP-47	RKRH	Vκ2	DPK-15	MQALQTLT	M	4	1
FITC-BSA	H05	VH3	DP-47	RSKT	Vκ2	DPK-15	MQALQTRT	M	4	1
FITC-BSA	H02	VH3	DP-47	RWSF	Vλ1	DPL-3	AAWDDSLV	M	4	1
FITC-BSA	E06	VH3	DP-47	AKFRL	Vκ2	DPK-15	MQALRTRT	M	3	1
FITC-BSA	E11	VH3	DP-47	AYHGR	Vκ2	DPK-15	MQALQTRT	M	3	1
FITC-BSA	C02	VH3	DP-47	GKVLG	Vκ2	DPK-15	MQALQTPT	Im	4	1
FITC-BSA	B02	VH3	DP-47	GKVLG	Vκ2	DPK-15	MRALQTPT	Im	3/4	2
FITC-BSA	E07	VH3	DP-47	GSSRT	Vλ1	DPL-3	AAWDDSLPGYV	M	3	1
FITC-BSA	E08	VH3	DP-47	KRMDG	Vκ2	DPK-15	MQALQTRT	M	3	1
FITC-BSA	A10	VH1	DP-10	LKRGH	Vλ1	DPL-3	AAWDDSLGFV	Im	3	1
FITC-BSA	D09	VH3	DP-47	LRREY	Vκ2	DPK-15	MQALRTRT	Im	4	1
FITC-BSA	G12	VH3	DP-47	RAGRD	Vλ1	DPL-3	AAWDDSLFLV	M	4	1
FITC-BSA	D03	VH3	DP-47	LKSAYK	Vκ2	DPK-15	MQALQTPT	Im	4	1
FITC-BSA	C12	VH3	DP-47	LNVRPK	Vκ2	DPK-15	MQALQTRT	Im	4	1
FITC-BSA	B10	VH3	DP-47	SRGKSM	Vκ2	DPK-15	MQALRTRT	Im	3	1
FITC-BSA	E09	VH3	DP-47	IRFRNAT	Vκ2	DPK-15	MQALRTRT	M	3	1
FITC-BSA	B09	VH3	DP-47	LKTSTPV	Vκ2	DPK-15	MRALQTPT	Im	3/4	2
FITC-BSA	G10	VH3	DP-47	LSRAFTM	Vκ2	DPK-15	MQALRTRT	M	4	1
FITC-BSA	E03	VH3	DP-47	LSRAFTM	Vκ2	DPK-15	MQALQTRT	M	3	1
FITC-BSA	B07	VH4	DP-67	AQRKYFDY	Vκ2	DPK-12	MQSIQLRT	Im	3	1
FITC-BSA	D01	VH4	DP-67	DLRKHFYD	Vκ1	DPK-9	QQSYSTRT	Im	4	1
FITC-BSA	E10	VH4	DP-67	DRWRVFDY	Vλ1	DPL-2	AAWDDSLSIV	M	3	1
FITC-BSA	A09	VH1	DP-14	KGLRLFDY	Vλ1	DPL-3	AAWDDSLV	Im	3	1
FITC-BSA	G08	VH3	DP-58	KKYQSAAR	Vκ2	DPK-19	MQGTHWPT	M	4	1
FITC-BSA	B03	VH4	DP-67	KTRRRFDY	Vκ2	DPK-15	MQALHTRT	Im	3	1
FITC-BSA	C03	VH4	DP-67	KTRRRFDY	Vκ2	DPK-15	MQALQTRT	Im	4	1
FITC-BSA	G11	VH3	DP-47	PYAKRFDY	Vκ2	DPK-15	MQALQTRT	M	4	1
FITC-BSA	G03	VH3	DP-47	RFARFDFY	Vλ3	DPL-16	NSRDSSGSV	M	4	3
FITC-BSA	A04	VH4	DP-67	RSFVGYEI	Vλ1	DPL-3	AAWDDSLV	Im	3	2
FITC-BSA	D06	VH4	DP-67	RWGRTFDY	Vκ2	DPK-15	MQALQTRT	Im	4	1
FITC-BSA	C06	VH1	DP-7	SQKRLITG	Vκ2	DPK-15	MQALQTRT	Im	4	1
FITC-BSA	C01	VH1	DP-7	SQKRLITG	Vκ3	DPK-22	QQYGSSPYT	Im	4	1
FITC-BSA	H04	VH4	DP-67	SRKRAFDY	Vκ2	DPK-15	MQALQTRT	M	4	1
FITC-BSA	C08	VH4	DP-67	SWVSGFDY	Vκ1	DPK-9	QQSYSTRT	Im	4	2
FITC-BSA	D04	VH1	DP-7	SYHRTFDY	Vκ1	DPK-5	QQANSFAAT	Im	4	1
FITC-BSA	C05	VH1	DP-7	SYHRTFDY	Vκ1	DPK-5	QQANSFPAT	Im	4	1
FITC-BSA	D05	VH1	DP-7	THSKTFDY	Vλ8	DPL-21	VLYMGSGVYV	Im	4	1
FITC-BSA	B12	VH3	DP-47	TRSSSYGE	Vκ2	DPK-15	MQALRTRT	Im	3	1
FITC-BSA	B04	VH4	DP-66	WSRETNY	Vλ1	DPL-3	AAWDDSLWSAV	Im	3	1
FITC-BSA	A07	VH3	DP-47	RTRGALPRN	Vλ1	DPL-3	AAWDDSLPRRLV	Im	3	1
FITC-BSA	A02	VH3	DP-47	YRFSAPPRD	Vλ1	DPL-3	AAWDDSLPSGV	Im	3	1
FITC-BSA	E04	VH3	DP-47	RFNRLSPRRA	Vκ2	DPK-15	MQALQTRT	M	3	1
FITC-BSA	B05	VH1	DP-25	SSVMGRVPVM	Vκ2	DPK-15	MQALQTLT	Im	3	1
FITC-BSA	E05	VH3	DP-47	TSCKLHSPRT	Vλ1	DPL-3	AAWDDGLLRV	M	3	1
FITC-BSA	D11	VH5	DP-73	GRGRPSMAYDV	Vλ1	DPL-3	AAWDDSLALV	Im	4	1
FITC-BSA	B08	VH3	DP-47	RSQVSRKYYTI	Vκ2	DPK-15	MQALRTRT	Im	3	1
Plasmin	MP01	VH3	DP-47	MTPOFFDY	Vκ2	DPK-15	MRALQTPT	Im	4	1
Plasmin	MP02	VH4	DP-67	SAYSIFYDY	Vλ3	DPL-16	NSRDSSGFQLV	Im	4	1

Table III. Continued

Antigen ^a	Clone	Heavy chains ^b			Light chains ^c			Selection method ^d	Round ^e	No. of copies ^f
		Family	Segment	CDR3 ^g	Family	Segment	CDR3 ^g			
t-PA	MT09	VH1	DP-7	DSGLGDPAL	Vλ2	DPL-11	SSYTSSSTLV	Im	4	1
t-PA	MT03	VH1	DP-7	DSGLGEPAL	Vλ2	DPL-11	SSYTSSSTLG	Im	4	1
t-PA	MT06	VH1	DP-7	DSGLGEPAL	Vλ2	DPL-11	SSYTSSSTLV	Im	4	1
t-PA	MT01	VH1	DP-7	ESGLGDPAL	Vλ2	DPL-11	SSYTSSSTLV	Im	4	1
t-PA	MT07	VH3	DP-47	TSRLKAHPS	Vλ1	DPL-8	QSYDSNLRV	Im	4	1
u-PA	MU02	VH3	DP-47	TSRLKAHPS	Vκ2	DPK-15	MRALQIPT	Im	4	1
u-PA	MU01	VH3	DP-47	TSRLKAHPS	Vκ1	DPK-8	QLNSYPT	Im	4	1
u-PA	MU03	VH3	DP-47	TSRLKAHPS	Vλ3	DPL-16	NSRDSGFLV	Im	4	1
HGF/SF	MH10	VH3	DP-47	GRQSRL	Vκ1	DPK-5	QQANSFPIT	Im	4	1
HGF/SF	MH19	VH3	DP-42	KFPFHGD	Vκ1	DPK-8	QLNSYPT	Im	4	1
HGF/SF	MH22	VH3	DP-42	KFPFHGD	Vκ1	DPK-5	QQANSFPIT	Im	4	4

^aThe region of the monoclonal antibody NQ11/7.22 (NQ11) bound by the Fab is indicated (Fv or Fc region); three Fabs bound neither fragment and therefore probably interacted with the CH1, Cκ or hinge region. Hapten-BSA binding clones listed did not bind BSA alone.

^bHuman germline V_H gene segments are assigned to families as in Tomlinson *et al.* (1992).

^cHuman germline V_κ gene segments (Cox *et al.*, 1994) are assigned to subgroups as in Kabat *et al.* (1991) and human germline V_λ gene segments (Williams and Winter, 1993) are assigned to families as in Chuchana *et al.* (1990).

^dIm, selected using antigen-coated immunotubes; M, selected using biotinylated antigen and streptavidin-coated paramagnetic beads. Numbers refer to how many rounds of selection the library had undergone when Fabs with the sequence indicated were isolated.

^eThe number of independent clones which were isolated with the same sequence.

^fCDR3 (complementarity determining region 3) for both heavy and light chains are as defined by Kabat *et al.* (1991).

^gThese genes appear to have been created by cross-overs between two V genes during PCR amplification.




Fig. 4. Use of human germline V gene segments. Frequencies of use of human V_H, V_κ and V_λ segments from the synthetic repertoire (A, C and E), or from natural antibodies (B, D and F). Frequencies (*f*) are plotted as % of total. V gene usage was compiled for the synthetic antibodies from Table III, and for natural antibodies, from the 292 rearranged V_H genes in the database described in Tomlinson *et al.* (1992), from the 236 rearranged V_κ genes in the database described in Cox *et al.* (1994) and from a database of 110 rearranged V_λ genes taken from the 'Entrez' sequence database (release 8.0; National Center for Biotechnological Information). V_H segments are listed by DP numbers (Tomlinson *et al.*, 1992), V_κ segments by DPK numbers (Cox *et al.*, 1994) and V_λ segments by DPL numbers (Williams and Winter, 1993). All V gene segments listed were included in the synthetic repertoire except those marked (*). V_H gene segments (located on chromosome 15 or 16) which are not used *in vivo* (Tomlinson *et al.*, 1994), but which were included in the synthetic repertoire are indicated (#).

over the limited number of antigens, appears to differ from the usage *in vivo*.

Distribution of CDR3 lengths

We also analysed the lengths and sequences of the CDR3 loops in the selected Fab fragments (Table III; Figure 5).

All the heavy chain CDR3 lengths included in the synthetic repertoire were present. The four residue loops almost all include a glycine residue, presumably to make the tight turn. However, the distribution of the heavy chain CDR3 lengths, biased towards short lengths, contrasts with natural antibodies. This appears to be especially characteristic of




Fig. 5. Distribution of CDR3 lengths. Length distribution of CDR3 loops in human V_H , V_K and V_L chains from the synthetic repertoire (A, C and E), or from natural antibodies (B, D and F). Frequencies (f) are plotted as % of total. Data were compiled as in Figure 4 legend, except that for natural rearranged V_H genes the data was taken from the 177 human genes described by Wu *et al.* (1993). All CDR lengths listed were included in the synthetic repertoire except for those marked (#).

the synthetic Fab fragments binding to hapten-BSA conjugates; those fragments binding to protein antigen appear to have longer CDR3 lengths. The distribution of CDR3 lengths for the synthetic λ light chains was similar to natural antibodies, but differed for the κ light chains, with no loops of 10 residues seen in the synthetic chains.

Pairings of heavy and light chains

The distribution of heavy and light chain pairings (Figure 6) identified some 52 different segment pairings among the 137 unique clones. Several V_H gene segments were found paired with several V_K and V_L gene segments, for example DP-7, DP-38, DP-47 and DP-67 were each found in combination with several different light chain segments. Likewise, the light chain segments DPK-15 and DPL-3 were found in combination with several heavy chain segments. Not surprisingly these segments correspond to those used with higher frequency (see above). The usage of V gene segments differs for antibodies of different specificity, and the pattern of pairings provides a 'fingerprint', readily distinguishing the 'response' to different antigens. Some pairings, for example DP-47 with DPK-15, and DP-47 with DPL-16, were also present in Fab fragments of different specificities.

There were also several examples of 'promiscuous' pairings (Clackson *et al.*, 1991), chains that bind to the same antigen with any of several partner chains (Table III). For example, in the Fab fragments binding to NIP-BSA, the same heavy chain sequence (DP-38 segment with CDR3 of sequence AGTL) was paired with six different light chains of V_{K2} , V_{L1} and V_{L3} families

(segments DPK-12, DPL-3 and DPL-16, respectively). Likewise in Fab fragments binding to FITC-BSA, the same light chain sequence (DPK-15 segment with CDR3 of sequence MQALQTRT) was paired with 15 different heavy chains of V_{H1} , V_{H3} and V_{H4} families (DP-7, DP-47 and DP-67 segments, respectively).

Affinities of selected antibodies

Soluble Fab fragments were produced and purified via their hexahistidine tag by immobilized metal chelate affinity chromatography (IMAC), with typical yields of 100–500 $\mu\text{g/l}$. From the large (6.5×10^{10} clones) repertoire we measured the affinities of several Fab fragments binding to soluble NIP-CAP or fluorescein by fluorescence quench titration (Eisen, 1964). The affinities (K_d) of the Fab fragments ranged from 3.8 to 217 nM (Table IVA). This shows that high affinity anti-hapten antibodies can be isolated directly from large antibody repertoires. We also characterized three Fab fragments binding to the haptens NIP-CAP and fluorescein after selection of a small fraction (10^7 clones) of the repertoire on NIP-BSA or FITC-BSA. In contrast these affinities (K_d) ranged from 0.8 to 12 μM (Table IVB).

We measured kinetics and affinity of Fab fragments (from the 6.5×10^{10} clone repertoire) binding to immobilized monoclonal antibody NQ11/7.22 and HGF/SF by surface plasmon resonance (Table IVA). For the Fab fragments against the variable region (NML1) and the Fc portion (NML9) of antibody NQ11/7.22, the binding affinities were determined both by on- and off-rate analysis and by Scatchard plots of equilibrium binding (see Figure 7) to be in the range 30–60 nM. For NML1, the on-rate was calculated as $6.4 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ and the off-rate as $2.2 \times 10^{-2} \text{ s}^{-1}$; for NML9 as $5.2 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ and $3 \times 10^{-2} \text{ s}^{-1}$, respectively. However for the Fab fragment (MH22) against HGF/SF, Scatchard analysis indicated several classes of binding sites, with affinities from micro- to nanomolar. At low Fab concentrations (<40 nM), where high affinity interactions predominate, the affinity could be estimated as 7 nM from an initial on-rate of $1.7\text{--}1.9 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ and off-rate of $1.3 \times 10^{-2} \text{ s}^{-1}$.

Discussion

In the immune system, antibodies with moderate affinities are selected from primary repertoires, and their affinities improved step-wise by rounds of somatic mutation and selection. However, theoretical arguments based on the idea of 'shape space' have suggested that larger and more diverse repertoires should give rise to higher affinity antibodies (Perelson and Oster, 1979). The probability (P) that an epitope is recognized by at least one antibody in a repertoire depends on the probability (p) that an antibody recognizes a random epitope with an affinity above a threshold value, and on the number of antibodies (N) according to the equation $P = 1 - e^{-Np}$ (Perelson and Oster, 1979). This predicts, as expected, that the larger the repertoire, the greater the chances of finding a high affinity antibody. However it does not provide an explicit relationship between repertoire size and affinity.

Here we used a repertoire of phage antibodies as an 'artificial immune system' to explore the possibility of




Fig. 6. Pairings of heavy and light chain V gene segments in the synthetic repertoire. Data were compiled and are listed as described in Figure 4 legend. Fab fragments binding NIP-BSA are indicated by black diamonds; Fab fragments binding FITC-BSA by open circles; and Fab fragments binding antibody NQ11/7.22, plasmin, u-PA, t-PA or HGF/SF by open squares.

isolating high affinity antibodies directly from a very large primary antibody repertoire. Previously the size of phage antibody repertoires has been limited to $<10^9$ clones by the efficiency of transfection of DNA into bacteria: here we have used the process of combinatorial infection and *in vivo* recombination (Waterhouse *et al.*, 1993) to overcome this. Bacteria harbouring a repertoire of heavy chains (encoded on a plasmid replicon) were infected with phage encoding a repertoire of light chains, and the heavy chain genes translocated to the phage replicon by recombination within the bacterium. By this means we were able to make a repertoire of 6.5×10^{10} clones and obtained antibodies to a range of antigens and haptens (Table II) with affinities <10 nM (Table IVA). With a smaller repertoire (10^7 clones) we only found antibodies of moderate affinities (>800 nM), in agreement with earlier work in which antibody fragments isolated from smaller repertoires (10^7 – 10^8 clones) were found to have affinities of 700 nM for the hapten NIP (Hoogenboom and Winter, 1992) and 140 nM for the hapten fluorescein

(Barbas *et al.*, 1992c, 1993). The characterization of repertoires of different sizes (and of known diversity) should help in defining the explicit relation between repertoire size and affinity.

As shown in Figure 8, the binding affinities of secondary response (hypermutated) mouse monoclonal antibodies to the haptens NIP and fluorescein were similar to those of human Fab fragments isolated directly from the large repertoire. Only a single mouse anti-NIP antibody has been described (Lucisano-Valim and Lachmann, 1991) with an affinity ($K_d = 5.6$ nM) similar to the best human Fab fragment ($K_d = 4.0$ nM; Table IVA). However, eight mouse monoclonal antibodies have been described with higher affinities for fluorescein than the best human Fab fragment ($K_d = 3.8$ nM; Table IVA), the best of these (4-4-20) with an affinity of 0.19 nM (Bedzyk *et al.*, 1986).

It is quite possible that antibody fragments with even higher affinities are present in the repertoire, as we had designed the selection process to capture antibody fragments with a range of binding affinities to antigen,

Table IV. Sequences and affinities of Fab fragments**(A) Fabs from 6.5×10^{10} repertoire**

Antigen	Clone	Heavy chain		Light chain		K_d (nM)
		segment	CDR3	segment	CDR3	
NIP-CAP	NIP-G6	DP-38	AGTL	DPK-12	MQSIQLPT	4.0 (± 0.1)
NIP-CAP	NIP-G10 ^c	DP-38	AGTL	DPK-12	MQSIQLPAT	5.4 (± 0.2)
NIP-CAP	NIP-H1 ^c	DP-38	KGSE	DPL-3	AAWDDSLAWFV	11.3 (± 0.4)
NIP-CAP	NIP-C11	DP-38	PGYRGTR	DPL-3	AAWDDSLSAYV	16.5 (± 0.5)
NIP-CAP	NIP-H3 ^c	DP-38	HGQH	DPL-3	AAWDDSLCPEFV	19.7 (± 1.7)
NIP-CAP	NIP-G11 ^c	DP-47	PLNSKKN ^b TTTQ	DPL-3	AAWDDSLFYV	20.1 (± 3.6)
NIP-CAP	NIP-G9 ^c	DP-38	AGTL	DPL-3	AAWDDSLV	22.0 (± 1.0)
NIP-CAP	NIP-E5 ^c	DP-38	PNGDQ	DPL-3	AAWDDSLAFV	22.1 (± 0.8)
NIP-CAP	NIP-E7 ^c	DP-38	GGTQ	DPL-3	AAWDDSLV	29.8 (± 1.1)
NIP-CAP	NIP-A4	DP-38	PATRS	DPK-15	MQALQTPLT	48 (± 1.0)
NIP-CAP	NIP-C9	DP-38	GGKD	DPL-18	LLYYGGAYV	59 (± 3.0)
Fluorescein	FITC-B4	DP-66	WSRETNYS	DPL-3	AAWDDSLWSAV	3.8 (± 0.4)
Fluorescein	FITC-A4	DP-67	RSFVGYEI	DPL-3	AAWDDSLV	14.3 (± 2.0)
Fluorescein	FITC-B11	DP-47	IGQF	DPL-3	AAWDDSLAFV	24.1 (± 0.8)
Fluorescein	FITC-B7	DP-67	AQRKYFDY	DPK-12	MQSIQLRT	151 (± 3.0)
Fluorescein	FITC-A2	DP-47	YRFSAPPRD	DPL-3	AAWDDSLPSGV	217 (± 16.0)
NQ11 (Fv)	NML1	DP-47	ASSPFVLQ	DPL-21	VLYMGSGSAV	32 ^a and 34 ^b
NQ11 (Fc)	NML9	DP-14	GTGLDG	DPL-10	CSYAGSSYV	41 ^a and 58 ^b
HGF/SF	MH22	DP-42	KFPFHGD	DPK-5	QQANSFPIT	7 ^b

(B) Fabs from 1×10^7 repertoire

Antigen	Clone	Heavy chain		Light chain		K_d (μ M)
		segment	CDR3	segment	CDR3	
NIP-CAP	sNIP-D10	DP-53	PWARGTD	DPK-21	QQYNNWLST	8 (± 0.6)
NIP-CAP	sNIP-F3 ^c	DP-47	NYNAAFDY	DPL-21	VLYMGSGHRV	12 (± 1.3)
Fluorescein	sFITC-C2	DP-67	SGVRGLMT	DPK-9	QQSYSTRT	0.82 (± 0.14)

Affinities (K_d) for haptens were determined by fluorescence quench titration. Affinities (K_d) for protein antigens were determined by SPR, by Scatchard analysis^a and from analysis of the rate constants^b. All clones were derived from selections on immunotubes except for those marked^c which were derived from selections using magnetic beads. The residues in the light chain CDR3 regions encoded by randomized codons are in bold.

including those with only moderate affinity. Thus, we took advantage of the binding avidity of multiple Fab fragments on the surface of the phage (by using phage rather than phagemid vectors) and short wash times to retain phage with fast dissociation kinetics. Also for selections on immunotubes we used a high coating density of antigen to favour rebinding of the phage, and for selections with soluble biotinylated antigen we used a relatively high concentration of antigen (50 nM) to try to include even those phage with moderate equilibrium constants (Hawkins *et al.*, 1992). Presumably it would be possible to favour the selection of higher affinity antibodies from this repertoire by more stringent selection.

The phage repertoire was not only large, but also highly diverse. It was assembled from the majority of V gene segments used *in vivo*, including all the major V_H and V_L families, and V_K subgroups. The segments included all the major heavy and light chain CDR1 and CDR2 loop conformations (Chothia and Lesk, 1987; Chothia *et al.*, 1989, 1992), and the CDR3 loops were made of diverse sequences and lengths. The chains were paired at random (Huse *et al.*, 1989), creating diverse pairings. The repertoire was sufficiently large that several pairings of a single heavy or light chain could be isolated from the repertoire. Such chain 'promiscuity' is characteristic of repertoires derived from the mRNA from immune sources (see for




Fig. 7. Affinity of Fab NML1 by SPR. Binding of the Fab to a sensor chip surface coated with mouse monoclonal antibody NQ11/7.22. See Materials and Methods for further details. For each concentration of antibody (C, nM), the equilibrium binding signal (Req, in resonance units) was plotted against the Req/C. The slope gives the binding affinity (K_d) as 32.3 nM.




Fig. 8. Affinities for synthetic antibodies and mouse monoclonal antibodies. Affinity data for the Fab fragments from the synthetic repertoire were compiled from Table IVA. (A) Antibodies binding to NIP; data on the mouse immune response were taken from Mariuzza and Strand (1981), Cumano and Rajewsky (1986) and Lucisano-Valim and Lachmann (1991). (B) Antibodies binding fluorescein; data on the mouse immune response were taken from Kranz and Voss (1981), Kranz *et al.* (1982), Reinitz and Voss (1984), Bates *et al.* (1985), Bedzyk *et al.* (1986) and Denzin and Voss (1992).

example Clackson *et al.*, 1991) and reflects the chances of a chain making multiple pairings, which in turn depends on the frequency of the chain and the size of the repertoire.

In the antibodies binding to the haptens, the combinations of heavy and light chain segments appeared to be restricted. For example, the antibodies binding to soluble hapten NIP-CAP (Table IVA) mainly utilized the heavy chain segment DP-38 and the light chain segment DPL-3, and included a four residue heavy chain CDR3 loop with a distinctive motif, X-Gly-X-X. This is reminiscent of the restricted response seen with mouse antibodies raised by immunization with the hapten 4-hydroxy-3-nitrophenyl acetate (NP): the immune response in C57BL/6 mice is dominated by antibodies with $\lambda 1$ light chains paired with heavy chains encoded by the V186.2 V_H segment and the DF116.1 D segment (Bothwell *et al.*, 1981; Cumano and Rajewsky, 1985).

As *in vivo*, only a few segments contributed to most of the 'response'. However, the usage of V gene segments found in the selected Fab fragments from the artificial repertoire differed from that of antibodies from natural repertoires (Figure 4). This might reflect a different representation of segments in the primary repertoire, or the high frequency of sequences from phage antibodies directed against hapten conjugates. Nevertheless we would expect the artificial repertoire to be shaped by different selection pressures to those that operate *in vivo*, leading to a different spectrum of binding sites. If 'holes' exist in the natural repertoire, they may be absent in an artificial repertoire and vice versa. Despite the differences in segment usage between the natural and synthetic antibodies, there is one striking similarity: the heavy chain segment DP-47 is the most commonly used segment in both. *In vivo*, it has been suggested that pre-B cells displaying DP-47 heavy chains are selected by binding to autoantigen (Schwartz and Stollar, 1994). We suggest that the usage of DP-47 reflects a more fundamental property of this segment; the structure of the binding site may be more capable of accommodating a wider diversity of antigens than other segments (Figure 6).

We conclude that human antibodies with affinities in the nanomolar range, and specific for protein antigens and haptens, can be derived directly from large and diverse synthetic phage antibody repertoires. The binding affinities are typical of somatically mutated mouse antibodies produced *in vivo*, and presumably could be improved further through rounds of 'chain shuffling' (Marks *et al.*, 1992b) or point mutagenesis (Hawkins *et al.*, 1992) to create binding specificities and affinities outside the reach of the immune system. In addition, the use of synthetic phage antibody repertoires based on V gene segments to simulate natural immune systems may provide further insights into immune strategy, for example in helping to define the relationship between affinity and repertoire size, or the relationship between the structures of the antigen binding sites and the usage of V, D and J segments, CDR3 lengths and junctional diversity.

Materials and methods

Vectors

The 'acceptor' vector, into which light chain repertoires are cloned, fdDOG-2loxVkd1, is identical to fdDOG-2lox (Waterhouse *et al.*, 1993), except that the light chain variable region gene has been deleted (Figure 2A). The 'donor' vector, into which heavy chain repertoires are cloned, pUC19-2loxVHd1, is identical to pUC19-2lox (Waterhouse *et al.*, 1993), except that the heavy chain variable region gene has been deleted (Figure 2B). The vector for expression of soluble Fab fragments, pUC119His6mycXba, is a derivative of pUC119 (Vieira and Messing, 1987) in which the polylinker has been replaced by the sequence shown in Figure 2C.

Construction of synthetic heavy chain repertoires

A diverse repertoire of rearranged V_H genes has previously been built *in vitro* (Nissim *et al.*, 1994) from a bank of 49 cloned V_H gene segments (Tomlinson *et al.*, 1992) [one of the 50 segments (DP-20) included in the repertoire of Nissim *et al.* (1994) was a pseudogene]. To these segments completely randomized CDR3 regions (Kabat *et al.*, 1991) were appended, varying in size between four and 12 residues (Figure 1A). This cloned repertoire, with $>10^8$ different clones, was re-amplified using PCR with primers pUC-reverse and JH-Xho-FOR (Table VA), the DNA was cut with *Nco*I and *Xho*I, and ligated into pUC19-2loxVHd1. The ligation mixture was electroporated (Dower *et al.*, 1988) into *E. coli*

Table V. Oligonucleotides

A. Re-cloning of synthetic human VH repertoires into pUC19-2loxVHdel

pUC-reverse 5'- AOC GGA TAA CAA TTT CAC ACA GG
 JH-Xho-FOR 5'- GCC TGA ACC GCC TCC ACC ACT GGA GAC GGT GAC CAG GGT ACC TTG GCC CCA

B. Construction of synthetic human kappa chain repertoires

1. Amplification of human Cκ

CκFOR 5'- CTG CTA TTA TCG GGC GCG CTT TTA TTA ACA CTC TCC CTT GTT GAA GCT CTT TOT GAC GGG
 CκLink 5'- ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA COT ACT GTG GCT GCA CCA TCT GTC

2. Human Vκ back primers

SYNκB1	5'- CAT GAC CAC AGT GCA CTT GAC ATC CAG WIG ACC CAG	DPK1,4,5,6,7,8,9,11
SYNκB2	5'- CAT GAC CAC AGT GCA CTT GTC ATC TGG ATG ACC CAG	DPK10
SYNκB3	5'- CAT GAC CAC AGT GCA CTT GTC ATC CAG ATG ACC CAG	DPK3
SYNκB4	5'- CAT GAC CAC AGT GCA CTT GAT ATT GTG ATG ACC CAG	DPK15,18,19
SYNκB5	5'- CAT GAC CAC AGT GCA CTT GAT ATT GTG ATG ACC CAG	DPK12,13,14,16,17
SYNκB6	5'- CAT GAC CAC AGT GCA CTT GAA ATT GTG ATG ACC CAG	DPK20,22
SYNκB7	5'- CAT GAC CAC AGT GCA CTT GAA ATA GTG ATG ACC CAG	DPK21
SYNκB8	5'- CAT GAC CAC AGT GCA CTT GAC ATC GTG ATG ACC CAG	DPK24
SYNκB9	5'- CAT GAC CAC AGT GCA CTT GAT GTT GTG ATG ACC CAG	DPK25
SYNκB10	5'- CAT GAC CAC AGT GCA CTT GAA ATT GTG CTT ACT CAG	DPK26
SYNκB11	5'- CAT GAC CAC AGT GCA CTT AAC ATT CAG ATG ACC CAG	DPK2
SYNκB12	5'- CAT GAC CAC AGT GCA CTT GAA ATT GTA ATG ACC CAG	DPK23

3. Human Vκ forward primers encoding synthetic CDR3s

DPK1FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GAG ATT ATC ATA CTG TTG AC	DPK1
DPK2FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GTA ACT ATT ATG CTG TAG AC	DPK2
DPK3FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GTA ATT GTA ATC TTG TAG AC	DPK3
DPK4FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GGC ACT GTT ATA CTT TTG AC	DPK4
DPK5/6FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GAA ACT GTT AGC CTG TTG AC	DPK5,6
DPK7FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GTA ACT ATT ATA CTG TTG AC	DPK7
DPK8FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GTA ACT ATT AAG CTG TTG AC	DPK8
DPK9FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GGT ACT GTA ACT CTG TTG AC	DPK9
DPK10FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GAA ACT ATA CTG TTG AC	DPK10
DPK11FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GGC ATT GTA AGT CCG TTG AC	DPK11
DPK12FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AAG CTG TAT ACT TTG CAT GC	DPK12
DPK13FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AAA CTC TAT AGC TTG CAT GC	DPK13
DPK14FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG ATC TTG TCC ATC TTG CAT GC	DPK14
DPK15FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AGT TTG TAG AGC TTG CAT GC	DPK15
DPK16FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AAA TTG TOT AGC TTG CAT GC	DPK16
DPK17FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AAA TTG TOT AGC TTG CAT GC	DPK17
DPK18/19FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG CCA GTG TOT ACC TTG CAT GC	DPK18,19
DPK20/22FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG TGA CTT ACC ACC ATA CTG CTG AC	DPK20,22
DPK21FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG CCA GTT ATT ATA CTG CTG AC	DPK21
DPK23FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG TAA GTT ATA ATC CTG CTG AC	DPK23
DPK24FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG AGT ACT ATA ATA TTG CTG AC	DPK24
DPK25FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG GTG CTT ATT GCC CTG CTG AC	DPK25
DPK26FOR	5'- CTT GGT CCC TTG GCC GAA CGT (MMN) ₀₋₂ MNG TAA ACT ACT ACT CTG ATG AC	DPK26

C. Construction of synthetic human lambda chain repertoires

1. Amplification of human Cλ2

CL2FOR1 5'- GGA ATT CCG GGT GAG GGT TGA GAA
 CL2BACK1 5'- CCC GGA AGC TTC TGC CCC TCA TCC
 CL2BACK2 5'- GTA TTC GCG GAG GGG ACC AAG CTG ACC GTC CTA GGT CAG CCC AAG GCT GCC CCC TCG GTC ACT
 HuCAFORCYSASCNOT 5'- GAG TCA TTC TCG ACT TGC GGC CGC CTG CTA TTA TCG GGC GCG CTT TTA TTA TGA AGA TTC TOT AAG
 GGC CAC TOT CTT

2. Human Vλ back primers

DPVλ1a	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACG CAG CCG CC	DPL4,5,8,9
DPVλ1b	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACG CAG CCG CC	DPL6,7
DPVλ1c	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACT CAG CCA CC	DPL1,2,3
DPVλ2	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACT CAG CCA CC	DPL10,11,12,13,14
DPVλ3a	5'- CAT GAC CAC AGT GCA CTT TCT TCT GAG CTG ACT CAG CCA CC	DPL16
DPVλ3b	5'- CAT GAC CAC AGT GCA CTT TCC TAT GAG CTG ACT CAG CCA CC	DPL23
DPVλ7/8	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACT CAG CAG CC	DPL22,24
DPVλ9	5'- CAT GAC CAC AGT GCA CTT CAG TCT GTG TTG ACT CAG CCA CC	DPL18,19,21

3. Human Vλ forward primers encoding synthetic CDR3s

DPL1/2/3V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₅ --- CAG GCT GTC ATC CCA TCC TCC ACA GTA	DPL1,2,3
DPL4V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- CCG GCT GGT ATC CCA TCC	DPL4
DPL4V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ TCT CCG GCT GGT ATC CCA TCC TAA GCA GTA	DPL4
DPL5V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- CAG GCT GCT ACC CCA TOT	DPL5
DPL5V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₄ ACT CAG GCT GCT ATC CCA TOT TCC GCA CTA	DPL5
DPL6/7/8V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- CAG GCT GCT GTC ATA GGA	DPL6,7,8
DPL6/7/8V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₂ ACT CAG GCT GCT GTC ATA GGA CTG GCA GTA	DPL6,7,8
DPL9V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- CAG GCT GTT ATC CCA TCC	DPL9
DPL9V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₁ ATT CAG GCT GTT ATC CCA TCC TTT GCA GTA	DPL9
DPL10V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- GCT ACT ACC TGC ATA TGA	DPL10
DPL11/13V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- GCT GCT GCT TOT ATA TGA GCT GCA GTA	DPL11,13
DPL11/13V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₂ AGT GCT GCT GCT TOT ATA TGA GCT GCA GTA	DPL11,13
DPL12V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- GTA GCT GCT TGC ATA TGA	DPL12
DPL14V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- GTA ACT ACT TGA ATA TAA	DPL14
DPL14V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₂ AGT GTA ACT ACT TGA ATA TAA GCT GCA GTG	DPL14
DPL16V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- ACC ACT GCT GTC CCG GGA	DPL16
DPL16V/JFORa	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₂ ATG GTT ACC ACT GCT GTC CCG GGA GTT ACA	DPL16
DPL18V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ AGC ACC ACC ATA GGA CAG	DPL18
DPL19V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- AGC ACC ACT ATA GGA CAG	DPL19
DPL21V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ GCT ACT ACC CAT ATA CAG	DPL21
DPL22V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₁ GAA GTT GCT CCG ACT GTC TGC CCC	DPL22
DPL23V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₃ --- AGT GCT GCT GTC CCA GCG CTG ACA GTA	DPL23
DPL24V/JFOR	5'- CTT GGT CCC TCC GCC GAA TAC (MMN) ₀₋₁ GAC TTG GCC ATC AAT CGT GTG GCT CTC TCC	DPL24

D. Sub-cloning of selected repertoires for expression of soluble Fab fragments

fδSEQ1 5'- GAA TTT TCT GTA TGA GG
 G3LXbaGTGBack 5'- GTC CTC GCA ACT TGC TCT AAG CAA TTT CAC AGT AAG GAG GTT TAA CTT GTG AAA AAA TTA TTA TTC GCA ATT

E. Sequencing and probing

TNFCDR3PRB	5'- CCT TGG AAG GCA GCA GC
Cκ.lib.seq	5'- CAA CTG CTC ATC AGA TGG CG
Cλ.lib.seq	5'- GTG GCC TTG TTG GCT TGA AGC
CH1.lib.seq	5'- GGT GCT CTT GGA GGA GGG TGC
peliback	5'- GAA ATA CTT ATT GCC TAC GG
LM33	5'- CAG GAA ACA CTT ATG AC
fδPCRback	5'- GCG ATG GTT GTT GTC ATT GTC GGC

A = adenosine; C = cytosine; G = guanine; T = thymidine; Y = C or T; R = A or G; W = A or T; S = G or C; K = T or G; M = C or A
 Restriction sites are underlined. Primer names are to the left of the sequences and the V-gene segments amplified to the right.

TG1 (Gibson, 1984) to create the library pUC19-2loxVHlib, and in total 5×10^8 clones were obtained. Diversity was confirmed by *Bst*NI fingerprinting (Clackson *et al.*, 1991) and sequencing of 24 independent clones. All these clones were found to be different.

Construction of synthetic kappa chain repertoires

The human C_k gene was amplified from the vector pSW1/FabD1.3 (Skerra *et al.*, 1991) by PCR with Taq polymerase using primers CxFOR and CxLink (Table VB1) which introduce a consensus human J_k segment at the 5'-end of the C_k gene and two stop codons (TAA) and an *Asc*I site at the 3'-end. The reaction mixture (50 μ l) was cycled 25 times (94°C for 1 min, 60°C for 1 min, 72°C for 1 min). The amplified C_k gene was purified using Magic PCR Preps (Promega) and resuspended in 50 μ l water.

In parallel, 26 human germline V_k gene segments with open reading frames (DPK1-26), which had been cloned from the genomic DNA of a single individual (Cox *et al.*, 1994), were individually amplified with Back primers that introduce an *Apa*LI site at the 5'-end (see Table VB2) and Forward primers that append a portion of the J_k segment to the 3'-end (see Table VB3). For each segment three independent PCRs were performed with different Forward primers to construct CDR3 regions (Kabat *et al.*, 1991) of length eight, nine or 10 residues that included one, two or three residues of random sequence (Figure 1B). For each gene, a 50 μ l PCR was performed using Taq polymerase and toothpicked frozen glycerol stocks of *E. coli* infected with the appropriate M13 clone as template. Reactions were cycled 25 times (94°C for 1 min, 60°C for 1 min, 72°C for 1 min). The Forward primers (Table VB3) introduced length and sequence diversity into CDR3 corresponding to that observed *in vivo* (Kabat *et al.*, 1991).

The amplified V_k genes were each joined to the amplified C_k gene using PCR (Horton *et al.*, 1989). Assembly PCRs (25 μ l) used Taq polymerase, 1 μ l of amplified C_k and 0.8 μ l of the V_k gene PCR from above. The appropriate V_k Back primer was used for each gene (Table VB2) together with C_k FOR (Table VB1) and the reaction cycled 30 times (94°C for 1 min, 55°C for 1 min, 72°C for 2 min).

The PCR assembly reactions for each V_k gene were checked by agarose gel electrophoresis, then pooled with the other V_k genes according to CDR3 length, and the V_k - C_k genes purified using Magic PCR Preps. The pooled DNA was then cut with *Apa*LI and *Asc*I and digested DNA (~6 μ g) purified from a 1.5% low melting-point agarose gel using Magic PCR Preps. Approximately 1 μ g of the purified and cut V_k - C_k DNA from each pool was ligated in a 60 μ l volume with 1200 U of T4 DNA ligase (New England Biolabs) to ~5 μ g of digested fdDOG-2loxVkdcl vector [previously electroeluted from a 0.8% agarose gel (Sambrook *et al.*, 1990)]. DNA was purified from the ligation mixture using GeneClean II (Bio 101), resuspended in 30 μ l water, and electroporated (Dower *et al.*, 1988) into four 50 μ l aliquots of *E. coli* TG1. Cells were grown in 1 ml 2 \times TY broth containing 1% glucose for 1 h and then plated in 243 mm \times 243 mm dishes (Nunc) on TYE (Miller, 1972) medium with 12.5 μ g/ml tetracycline (TYE-TET). After overnight incubation at 37°C, colonies were scraped off the plates into 7 ml of 2 \times TY broth (Miller, 1972) containing 15% (v/v) glycerol for storage at -70°C.

The frequency of inserts was checked by PCR for each of the three pools and found to be 90% for CDR3 of eight residues, 100% for CDR3 of nine residues and 87% for CDR3 of 10 residues. The number of clones with light chains could then be calculated as 9.9×10^3 (CDR3 of eight residues), 1.5×10^4 (CDR3 of nine residues), 6.5×10^4 (CDR3 of 10 residues). Sequence diversity was confirmed by sequencing eight clones of each CDR3 length; all clones were found to be different. The pools were then combined, to create the library fdDOG-2loxVklb, corresponding to 9.0×10^4 light chains.

Construction of synthetic lambda chain repertoires

The human C_λ gene (Vasicek and Leder, 1990) was amplified from genomic DNA by PCR with Taq polymerase using primers CL2BACK1 and CL2FOR1 (Table VC1) based in the regions flanking the C_λ exon. The *Eco*RI and *Hind*III sites in CL2FOR1 and CL2BACK1, respectively, were used to clone the PCR product into M13mp19 (Yanisch-Perron *et al.*, 1985).

Twenty-one V_λ germline gene segments with open reading frames, previously cloned in M13mp19 (Williams and Winter, 1993), were individually amplified using PCR and Taq polymerase with back primers (Table VC2) which anneal to framework 1 (FR1) and introduce a 5' *Apa*LI site, and forward primers (Table VC3) which append a portion of the J_λ gene (Vasicek and Leder, 1990) to CDR3. CDR3 loops (Kabat *et al.*, 1991) of eight to 13 residues that included zero, one, two, three,

four or five residues of random sequence were encoded by the forward primers (Figure 1C). The number of residues of random sequence included was designed to match the pattern of V gene rearrangement seen *in vivo* and varied with the different V_λ segments used.

Each synthetically rearranged V_λ gene was individually joined to the human C_λ gene by PCR with Taq polymerase (Horton *et al.*, 1989). Each 50 μ l PCR assembly reaction contained ~1 ng of M13mp19 containing the C_λ gene, ~0.1 μ g of the V_λ gene, the appropriate (FR1) back primer (25 pmol) (Table VC2), the back primer CL2BACK2 (2.5 pmol) (Table VC1), which contains the 3' sequence of the J_λ gene linked to the 5' sequence of the C_λ gene, and the forward primer HUCAFORCYSASCNOT (25 pmol) (Table VC1) which appends two stop codons (TAA) followed by an *Asc*I site to the 3' of the C_λ gene. Reactions were cycled 30 times (94°C for 1 min, 65°C for 1 min, 72°C for 2 min).

The PCR assembly reactions were combined into a single pool and the V_λ genes digested and ligated into fdDOG-2loxVkdcl as described for the V_k - C_k gene pools (see above), thus creating the library fdDOG-2loxVklb. Ninety-two percent of clones were found to carry inserts of the correct size, corresponding to a repertoire size of 7.4×10^5 λ light chains. Thirty-three clones were sequenced to confirm the presence of each V_λ segment. All the sequences were different.

Combinatorial infection and in vivo recombination

To create a large combinatorial repertoire of heavy and light chains on an fd phage vector we used the strategy of combinatorial infection and *in vivo* recombination (Waterhouse *et al.*, 1993). This system uses the *lox*-Cre site-specific recombination system of bacteriophage P1 (Sternberg and Hamilton, 1981; Hoess *et al.*, 1982) to bring together heavy and light chain genes onto the same replicon.

Phage P1 lysates were made by thermal induction (Rosner, 1972). *E. coli* C600 Su⁻ (Appleyard, 1954) harbouring phage P1Cm c1.100 r⁻m⁻ (Yarmolinsky *et al.*, 1989) were grown in a 2 l baffled flask containing 1 l of 2 \times TY, 25 μ g/ml chloramphenicol, 10 mM MgSO₄ with vigorous shaking at 30°C to OD₆₀₀ of 0.6. The temperature was then raised quickly to 42°C by shaking in a 70°C water bath and then shaking continued for a further 35 min in a 40°C water bath. Shaking was then continued at 37°C until lysis was visible (usually ~1.5–2 h). The culture was then spun at 5000 g for 15 min at 4°C and 100 μ l chloroform added to the supernatant. P1 phage titres were measured by adding serial dilutions of the lysate to mid-log phase *E. coli* TG1 (Gibson, 1984) grown in 2 \times TY broth containing 5 mM CaCl₂, the mixture incubated for 30 min at 30°C to allow infection and then plated on TYE medium (Miller, 1972) containing 30 μ g/ml chloramphenicol. Chloramphenicol resistant colonies were counted after 24 h incubation at 30°C. The P1 titre of the lysate used for this library was 3×10^9 transducing units (t.u.) per ml.

10^9 *E. coli* TG1, harbouring the library of synthetic V_k genes (or the library of synthetic V_λ genes) cloned in fdDOG-2loxVkdcl, were used to inoculate 1 l of 2 \times TY broth containing 12.5 μ g/ml tetracycline (2 \times TY-TET) and the culture shaken for 20 h at 30°C in two 500 ml aliquots in 2 l baffled Erlenmeyer flasks. Phage were purified from the supernatant by precipitation with polyethylene glycol as in McCafferty *et al.* (1990), resuspended in PBS (phosphate buffered saline: 25 mM NaH₂PO₄, 125 mM NaCl, pH 7.0) and filtered through a 0.45 μ m sterile filter (Minisart, Sartorius). Phage were titred by infecting exponential phase *E. coli* TG1 (30 min, 37°C) and plating on TYE-TET. Yields were typically 10^{10} t.u. per ml of culture.

At various points during the recombination procedure aliquots of bacteria were removed and serial dilutions plated on TYE plates supplemented with 1% glucose and containing a variety of different antibiotics (100 μ g/ml ampicillin; 15 μ g/ml tetracycline; 30 μ g/ml chloramphenicol). From the number of colony forming units (c.f.u.) the overall repertoire size could be calculated. These points are indicated in the protocol below and the results are summarized in Table I (also see Results).

Approximately 10^9 *E. coli* TG1 harbouring the library of synthetic heavy chain genes cloned in pUC19-2loxVHdel (pUC19-2loxVHlib; see above) were used to inoculate 100 ml 2 \times TY broth containing 100 μ g/ml ampicillin and 1% (w/v) glucose (2 \times TY-AMP-GLU). An aliquot of bacteria was plated for c.f.u. determination (see Table I, sample point 1) and the rest of the culture grown overnight at 30°C. An aliquot of bacteria was then plated for c.f.u. determination (see Table I, sample point 2). Two 5 ml aliquots of the overnight culture were then used to inoculate two 500 ml aliquots of 2 \times TY-AMP-GLU in 2 l Erlenmeyer flasks and the cultures grown, shaking, at 37°C to an OD₆₀₀ of 0.5.

2×10^{12} t.u. of V_k library in fdDOG-2loxVkdcl were added to one

of the above cultures and 2×10^{12} t.u. of V_{λ} library in fdDOG-2loxV κ del were added to the other culture. Each culture was immediately split into 5×100 ml aliquots and each aliquot mixed with 1 l of 2 \times TY-AMP-GLU, pre-warmed to 37°C. These cultures were then incubated at 37°C, without shaking for 30 min, and then with shaking until an OD₆₀₀ of 0.4 was reached (~30 min). An aliquot of bacteria from the kappa infection and another from the lambda infection were plated for c.f.u. determination (see Table I, sample point 3).

CaCl₂ was then added to a final concentration of 5 mM and 200 ml phage PICm c1.100 r⁻ m⁻ lysate (6×10^{11} t.u. see above) were added to each 1 l flask (giving a multiplicity of infection of ~1). Incubation was continued at 30°C for 1 h, with a short burst of shaking every 15 min. The culture was then centrifuged at 5000 g for 15 min and the pellets resuspended in the original volume of 2 \times TY broth containing 100 µg/ml ampicillin, 12.5 µg/ml tetracycline, 25 µg/ml chloramphenicol and 1% glucose (i.e. 5 l for the V_{κ} library and 5 l for the V_{λ} library). An aliquot of bacteria was plated for c.f.u. determination (see Table I, sample point 4). The repertoire size was determined to be 6.5×10^{10} from the number of ampicillin, tetracycline and chloramphenicol resistant c.f.u. at this point (see Results). An aliquot of each culture was also centrifuged at 12 000 g for 5 min and the supernatant filtered through a 0.45 µm sterile filter (Minisart, Sartorius). The fd phage in the supernatant were titred by infecting exponential phase *E. coli* TG1 (30 min, 37°C) plating on TYE-TET (see Table I, sample point 5).

The cultures were incubated overnight at 30°C with shaking for 24 h in 2 l baffled flasks (1 l medium per flask). An aliquot of bacteria from each culture was plated for c.f.u. determination (see Table I, sample point 6). The fd phage in the supernatant were also titred by infection of exponential phase *E. coli* TG1 as above (see Table I, sample point 7). The total yield of fd phage was 4.1×10^{13} t.u. and therefore >99.9% were propagated from bacteria containing the pUC 'donor' vector and phage P1. The cultures were then centrifuged at 5000 g for 15 min at 4°C and the fd phage precipitated from the supernatant using polyethylene glycol (McCafferty *et al.*, 1990) and resuspended in a final volume of 10 ml PBS.

Ten 2 l flasks, each containing 1 l 2 \times TY broth were inoculated with *E. coli* TG1 and grown, shaking, at 37°C until an OD₆₀₀ of 0.4 (~ 4×10^{12} bacteria) was reached. Two microlitres of the above recombinant V_{κ} fd phage (8×10^{11} t.u.) were added to 5 l of *E. coli* and 2 ml of the above recombinant V_{λ} fd phage (2×10^{12} t.u.) were added to the other 5 l of *E. coli* and the cultures held at 37°C for 30 min without shaking and then for 30 min with shaking. The number of *E. coli* infected with fd phage was determined by plating bacteria on TYE-TET plates to be 1.7×10^{12} (V_{κ} repertoire) and 1.1×10^{12} (V_{λ} repertoire). This exceeds the estimated repertoire size by >10-fold, hence maintaining library diversity. Tetracycline was then added to 12.5 µg/ml and the culture shaken for 16 h at 30°C. The V_{κ} culture and the V_{λ} cultures were then centrifuged at 5000 g for 10 min and the pellet from each repertoire resuspended in 250 ml 2 \times TY broth containing 15% glycerol and stored in 15 ml aliquots at -70°C.

Aliquots of the two libraries were also spread on TYE-TET in 243 mm \times 243 mm dishes (Nunc). After overnight incubation at 30°C the number of colonies on the large plates was calculated from the number of colonies on small TYE-TET plates on which serial dilutions had been spread. Two plates, one containing 3.5×10^6 colonies of the V_{κ} library and the other containing 6.4×10^6 colonies of the V_{λ} library were selected, and the bacteria scraped into 10 ml 2 \times TY broth containing 15% glycerol. This stock therefore corresponded to a repertoire of 10^7 clones.

Assaying the efficiency of in vivo recombination

To test the efficiency of replacement of the anti-TNF heavy chain in the 'acceptor' vectors (fdDOG-2loxV κ lib and fdDOG-2loxV λ lib) with synthetic heavy chain from the 'donor' vector (pUC19-2loxVHlib), 250 individual colonies from each of the V_{λ} and V_{κ} recombinant libraries were picked onto TYE-TET plates and grown overnight at 30°C. Colony hybridization was then performed as in Tomlinson *et al.* (1992), with a primer (TNFCDR3PRB; Table VE) complementary to the CDR3 region of the anti-TNF heavy chain gene found in the 'acceptor' vectors (fdDOG-2loxV λ lib and fdDOG-2loxV κ lib). Where recombination is successful, the anti-TNF heavy chain gene should be replaced by the synthetic heavy chain from the 'donor' vector. Probing of the colonies indicated that only 12 V_{λ} colonies (5%) and 39 V_{κ} colonies (16%) retained the original heavy chain. Probing of 250 colonies from each of the V_{λ} and V_{κ} phage libraries before recombination indicated that, as expected, all colonies harboured the original heavy chain.

Clones lacking the anti-TNF heavy chain gene (42 V_{λ} , 48 V_{κ}) were

screened by PCR (Güssow and Clackson, 1989) for the presence of heavy chains with the primers pelBback and CH1.lib.seq (see Table VE) and for the presence of light chains with the primers fdPCRback and Ck.lib.seq (or CA.lib.seq). The probing and PCR screening indicated that in the recombinant V_{λ} library, 28% of clones had acquired a heavy chain from the donor vector and also had a lambda light chain gene; 5% were unrecombined fdDOG-2loxV λ lib; and 67% had deletions of the light chain, heavy chain or both. For the V_{κ} library, 28% of clones had acquired a heavy chain from the donor vector and also had a kappa light chain gene; 16% were unrecombined fdDOG-2loxV κ lib; and 56% had deletions of the light chain, heavy chain or both. Further cycles of infection (without selection) led to a further decrease in the frequency of phage harbouring heavy and light chain genes, presumably due to competition with deletion phage. Nevertheless, immediately after recombination, for both V_{λ} and V_{κ} repertoires, we can calculate that 28% of all fd phage clones had both heavy and light chain genes and that the heavy chain gene derived from the pUC 'donor' vector.

Propagation of phage from the recombinant library

Five litres of 2 \times TY-TET were inoculated with a 15 ml aliquot of the recombinant V_{κ} library glycerol stock (5×10^{10} c.f.u.) and a further 5 l 2 \times TY-TET inoculated with a 15 ml aliquot of the recombinant V_{λ} library glycerol stock (1×10^{11} c.f.u.). The cultures were grown, shaking, overnight at 30°C in baffled flasks (1 l medium per flask). The cultures were centrifuged at 5000 g for 15 min at 4°C and the fd phage precipitated from the supernatant using polyethylene glycol as in McCafferty *et al.* (1990) and each repertoire resuspended in a final volume of 10 ml PBS. Total phage yields (from 10 l) were typically around 10^{14} t.u.

Selection of the recombinant library on immunotubes

The phage repertoire was panned using immunotubes (Nunc; Maxisorp) coated with each antigen (Marks *et al.*, 1991; Griffiths *et al.*, 1993). A range of antigens was used, as described in Table II. Here we have focused on five protein antigens: a mouse monoclonal antibody (NQ11/7.22; Griffiths *et al.*, 1984); and four proteins belonging to the kringle-serine proteases family (HGF/SF, plasmin, t-PA and u-PA). In addition, selection was performed on two haptens conjugated to BSA (FITC Isomer I and NIP). FITC conjugated to BSA (FITC-BSA; 11.2 FITC groups per BSA molecule) was purchased from Sigma; NIP conjugated to BSA (NIP-BSA) was synthesized by coupling NIP-caproate-O-succinimide to BSA (Brownstone *et al.*, 1966) to give 27.9 NIP groups per BSA molecule. Tubes were coated with 10 µg/ml protein or 100 µg/ml hapten-BSA conjugates in PBS overnight at room temperature.

For the first round of selection 0.5 ml (6.4×10^{12} t.u.) of the recombinant V_{κ} library and 0.5 ml (7.5×10^{12} t.u.) of the recombinant V_{λ} library were used per immunotube. For the first two rounds of selection tubes were washed 10 times with PBS, 0.1% (v/v) Tween 20 and 10 times with PBS. For subsequent rounds of selection tubes were washed 20 times with PBS, 0.1% (v/v) Tween 20 and 20 times with PBS (Griffiths *et al.*, 1993). Phage were eluted with 100 mM triethylamine (Marks *et al.*, 1991). Eluted phage were used to infect 10 ml log phase *E. coli* TG1 cells and plated on TYE-TET medium in 243 \times 243 mm dishes (Nunc). After incubation overnight at 30°C the colonies were scraped off the plate into 200 ml 2 \times TY-TET and incubated, shaking, at 30°C for ~6 h. The culture was centrifuged at 5000 g for 15 min at 4°C and the fd phage precipitated from the supernatant using polyethylene glycol (McCafferty *et al.*, 1990), each repertoire being resuspended in a final volume of 2 ml PBS. The cell pellet was resuspended in 20 ml 2 \times TY broth containing 15% glycerol and a 2 ml aliquot stored at -70°C.

One millilitre of these phage (~ 10^{12} t.u.) was used per immunotube for the next round of selection. The library was subjected to four or five rounds of growth and selection for each antigen.

Selection of the recombinant library using streptavidin-coated paramagnetic beads

The library was also selected using soluble biotinylated, hapten-BSA conjugates and streptavidin-coated paramagnetic beads (Hawkins *et al.*, 1992), but with some modifications. FITC-BSA (11.2 FITC:BSA) and NIP-BSA (27.9 NIP-BSA) (see above) were biotinylated using Immopure NHS-SS-Biotin (sulfo succinimidyl 2-(biotinamido) ethyl-1,3'-dithiopropionate; Pierce) according to the manufacturer's instructions.

For the first round of selection 0.5 ml (6.4×10^{12} t.u.) of the recombinant V_{κ} library and 0.5 ml (7.5×10^{12} t.u.) of the recombinant V_{λ} library were made up to 2.5 ml with PBS and mixed with 2.5 ml PBS containing 4% skimmed milk powder, 50 µl Tween 20, and biotinylated hapten-BSA added to give a final concentration of 50 nM. The mixture

was then gently rotated on an inclined wheel for 1 h at room temperature. 1.5 ml of Dynabeads M-280 coated with Streptavidin (Dyna) [and previously blocked by incubating for 2 h at 37°C with PBS containing 2% skimmed milk powder (2% MPBS)] were then added and mixing continued for a further 15 min at room temperature. The Dynabeads were then washed a total of 15 times, using a Dynal MPC (Magnetic Particle Concentrator); each wash was with 1 ml PBS or with 1 ml 2% MPBS (every third wash). Phage were eluted from the beads by incubating 5 min at room temperature in 300 µl PBS, 50 mM dithiothreitol (DTT) and the eluate used to infect 10 ml log phase *E. coli* TG1 cells and plated on TYE-TET in 243×243 mm dishes (Nunc). Phage were harvested from the plates as above and each repertoire resuspended in a final volume of 2 ml PBS. The cell pellet was resuspended in 20 ml 2×TY broth containing 15% glycerol and a 2 ml aliquot stored at -70°C (see above).

For the second round (and subsequent rounds) of selection 1 ml of phage (~10¹² t.u.) were mixed with 0.5 ml PBS containing 6% skimmed milk powder, 10 µl Tween 20, and biotinylated hapten-BSA added to give a final concentration of 50 nM. Selection was then as above, except that only 300 µl of streptavidin-coated Dynabeads M-280 were used. The library was subjected to four or five rounds of growth and selection for each antigen.

ELISA screening of repertoire selections

'Polyclonal' mixtures of phage produced by re-propagation of the library after each round of selection were screened for binding to the antigen used for selection and to other control antigens by ELISA. The phage ELISA was performed essentially as McCafferty *et al.* (1990) using 10 µl PEG precipitated phage (~10¹⁰ t.u.), but using horseradish peroxidase conjugated anti-sheep antibody (Sigma) and 3',3',5',5'-tetramethylbenzidine (TMB) for detection. Reactions were stopped by the addition of H₂SO₄ after 10 min and readings taken by subtracting the A₆₅₀ from the A₄₅₀. All antigens were coated at 10 µg/ml in PBS.

Single tetracycline resistant colonies from infection of *E. coli* TG1 with eluted phage were also screened to identify those producing antigen-binding phage by ELISA essentially as in Clackson *et al.* (1991) except that phage were grown at 30°C, and detection was as for the polyclonal phage ELISA above.

Sub-cloning of selected repertoires for expression of soluble Fab fragments

Approximately 10⁸ bacteria harbouring phage fd were taken from the stocks frozen down after the appropriate round of selection (5 µl of a 10-fold dilution of the frozen stock). In general, these bacteria were used as template in a 50 µl PCR reaction and the heavy chain genes amplified by pre-soaking at 94°C for 10 min and then cycling 30 times (94°C for 1 min, 50°C for 1 min, 72°C for 2.5 min) using the primers fdSEQ1 and G3LXbaGTGBack (Table VD). The products were run on a 1.3% low melting point agarose gel and purified from the gel using 'Magic PCR Preps' (Promega). The DNA was then cut with *Xba*I and *Nor*I and ligated into pUC119His6mycXba. The ligation mixture was electroporated (Dower *et al.*, 1988) into *E. coli* TG1 and plated on TYE medium containing 100 µg/ml ampicillin and 1% glucose (TYE-AMP-GLU) and incubated at 37°C overnight.

Individual ampicillin resistant colonies were grown in 96-well plates and soluble Fab production induced with isopropyl β-D-thiogalactoside (IPTG) as in Marks *et al.* (1991). Soluble Fab fragments in supernatants were assayed for binding to antigen coated plates by ELISA. All antigens were coated at 10 µg/ml in PBS. Bound Fabs were detected with a mixture of rabbit anti-human λ light chain antibodies and rabbit anti-human κ light chain antibodies (Dako) followed by goat anti-rabbit IgG (whole molecule) peroxidase conjugate (Sigma), or by using a mixture of peroxidase conjugated sheep anti-human κ light chain (free and bound) antibodies and peroxidase conjugated sheep anti-human λ light chain (free and bound) antibodies (The Binding Site). ELISAs were developed with TMB as above.

Each antigen-binding clone was streaked on a TYE-AMP-GLU plate and two individual colonies picked and re-assayed for production of antigen-binding Fab fragments as above. Positive clones were stored in 2×TY, 15% glycerol at -70°C.

Sequencing of antibody V genes

Clones, toothpicked from frozen glycerol stocks, were amplified by PCR using Taq polymerase. Reactions (50 µl) were pre-soaked for 10 min at 94°C and then cycled 25 times (94°C for 1 min, 55°C for 1 min, 72°C for 30 s.). The primers were Cκ.lib.seq and LMB3 for kappa chain

amplification; Cλ.lib.seq and LMB3 for lambda chain amplification; and CH1.lib.seq and pelBback for heavy chain amplification (Table VE). Aliquots of the product were analysed on a 1.3% agarose gel. The remaining product was purified using Magic PCR Preps (Promega).

PCR cycle sequencing reactions with fluorescent dideoxy chain terminators (Applied Biosystems) (20 µl in 25 cycles: 96°C for 30 s, 50°C for 15 s, 60°C for 4 min) were carried out according to the manufacturer's instructions. The purified PCR product from above (200 ng) was used as template with the following primers: Cκ.lib.seq for kappa chains, Cλ.lib.seq for lambda chains and CH1.lib.seq for heavy chains (Table VE).

The sequencing reactions were analysed on an Applied Biosystems 373A Automated DNA Sequencer. Sequence analysis was performed using SeqEd (Applied Biosystems) and MacVector (IBI Kodak, New Haven, CT).

Epitope mapping of Fab fragments binding monoclonal antibody NQ11/7.22

The repertoire selected on the mouse monoclonal antibody NQ11/7.22 (γ1,κ; Griffiths *et al.*, 1984) was sub-cloned after the second, third and fourth round of selection for production of soluble Fab fragments. 161 out of 384 clones bound to NQ11/7.22 (see above), and were further mapped by binding to MOPC21 (an unrelated mouse γ1, κ monoclonal antibody; Sigma); mouse Fc fragment (Jackson); and NQ11/7.22 zero-linker diabody (containing only the heavy and light chain variable domains; Holliger *et al.*, 1993). All proteins were coated at 10 µg/ml in 50 mM NaHCO₃ (pH 8.3). Eleven different Fab fragments identified by sequencing (Table III) were thereby directly mapped to binding to the Fv (idiotypic) or Fc regions, or to the remaining portions of the monoclonal antibody.

Purification of Fabs and affinity determination

Several pUC119His6mycXba clones encoding NIP and fluorescein specific Fab fragments were chosen at random for affinity determination. A 1 l culture of *E. coli* TG1 (Gibson, 1984) harbouring each plasmid was grown and Fab expression induced with IPTG (De Bellis and Schwartz, 1990). After induction, the culture was shaken for 3 h at 25°C and the Fab fragments harvested from the periplasm, essentially as in Breitling *et al.* (1991).

The antibodies were purified by IMAC (Hochuli *et al.*, 1988; Hoffmann and Roeder, 1991). The pooled 'periplasmic fraction' and 'osmotic shock fraction' were passed over a 5 ml Ni-NTA resin (Diagen) according to the manufacturer's instructions. The column was washed with 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl, 35 mM imidazole and the protein was eluted by applying 50 mM sodium phosphate buffer pH 7.5, 500 mM NaCl and 100 mM imidazole. The eluted protein was dialysed against 2×3 l PBS for ~24 h. The dialysed fractions were then analysed by SDS-PAGE (Laemmli, 1970) under non-reducing conditions and the concentration determined spectrophotometrically (assuming A₂₈₀ of 1.0 = 0.7 mg/ml).

Affinities of the purified Fabs were determined by fluorescence quench titration with free hapten (Eisen, 1964), essentially as described by Foote and Milstein (1991). The haptens used were fluorescein (Sigma) or NIP-CAP. All measurements were made with a Hitachi F-4500 spectrofluorimeter, using an excitation wavelength of 280 nm and monitoring emission at 340 nm. Antibody (1.0 ml) in PBS was placed in a 10 mm×10 mm cuvette in the instrument, mixed continually using a magnetic stir-bar, and held at 20°C. Hapten additions were made automatically using a 50 µl gastight syringe (Hamilton) driven by a MicroLab M syringe controller (Hamilton). The titrations and data collection were performed automatically using a Dell 433/L computer interfaced with the syringe controller (through an RS-232 interface) and the spectrofluorimeter (through an IEEE interface and an instrument driver supplied by the manufacturer). The computer was programmed in QuickBasic (Microsoft). Data were averaged from two to five runs.

The binding of three of the Fab fragments binding protein antigens were analysed by SPR using the BIAcore system (Pharmacia Biosensor). The active concentrations of purified Fab fragments NML1 (anti-NQ11/7.22 Fv); NML9 (anti-NQ11/7.22 Fc) and MH22 (anti-HGF/SF) were determined by the measurement of mass transport-limited binding slopes (Karlsson *et al.*, 1993). The antibody NQ11/7.22 was purified from ascites by affinity chromatography (Mäkelä *et al.*, 1978) and 990 resonance units (RU) immobilized on the biochip by chemical coupling with NHS/EDC (Johnsson *et al.*, 1991; Chaiken *et al.*, 1992). HGF/SF was immobilized on the biochip after biotinylation. Thus 3.8 kRU of immobilized streptavidin (O'Shannessy *et al.*, 1992) were used to capture

2800 RU HGF which had been biotinylated with biotin-LC-hydrazide (Pierce) after periodate oxidation of the carbohydrate using a protocol based on O'Shannessy (1990), but with 20 mM Na₂SO₃ to quench excess periodate (Weber and Hof, 1975). After capture the hydrazone bond between the biotin and the HGF was stabilized by reduction with sodium cyanoborohydride (0.1 M in 0.1 M Na acetate pH 4: 40 µl at 2 µl/min). The fragments were passed over the surface at 5 µl/min at 25°C in concentrations ranging from 2 to 400 nM, and the dissociation constant determined by Scatchard analysis of the equilibrium binding, and on- and off-rate constants by a kinetics analysis software (Pharmacia Biosensor) (Karlsson *et al.*, 1991; Chaiken *et al.*, 1992).

Acknowledgements

We thank M.Yarmolinsky and N.Sternberg for helpful advice and the gift of several phage P1 strains. Also R.A.Mariuzza, S.Songsivilai, M.Bowles, V.V.Mesyanzhinov, K.P.Holliger, R.Hoet, R.de Wildt, C.de Lalla and D.Neri for practical help with the library construction and selection. A.D.G. was supported by the Cancer Research Campaign, O.H. and S.C.W. by MRC studentships, W.L.C. by the Plant Biotechnology Institute, National Research Council of Canada, P.W. by CSIRO Australia, I.M.T. by the Human Genome Mapping Programme and by Trinity College Cambridge, R.E.K. by Deutsche Forschungsgemeinschaft, N.M.L. by The Cambridge Commonwealth Trust, A.N. by the Human Frontier Science Programme Organization (HFSP), J.P.L.C. by the Nuffield Foundation and M.Z. by the CEC BIOTECH programme.

References

- Appleyard, R.K. (1954) *Genetics*, **39**, 440–452.
- Barbas, C.F., Kang, A.S., Lerner, R.A. and Benkovic, S.J. (1991) *Proc. Natl Acad. Sci. USA*, **88**, 7978–7982.
- Barbas, C.F. *et al.* (1992a) *Proc. Natl Acad. Sci. USA*, **89**, 9339–9343.
- Barbas, C.F., Crowe, J.E., Cababa, D., Jones, T.M., Zebede, S.L., Murphy, B.R., Chanock, R.M. and Burton, D.R. (1992b) *Proc. Natl Acad. Sci. USA*, **89**, 10164–10168.
- Barbas, C.F., Bain, J.D., Hoekstra, D.M. and Lerner, R.A. (1992c) *Proc. Natl Acad. Sci. USA*, **89**, 4457–4461.
- Barbas, C.F., Amberg, W., Simoncsits, A., Jones, T.M. and Lerner, R.A. (1993) *Gene*, **137**, 57–62.
- Bates, R.M., Ballard, D.W. and Voss, E.W. (1985) *Mol. Immunol.*, **22**, 871–877.
- Bedzyk, W.D., Reinitz, D.M. and Voss, E.W. (1986) *Mol. Immunol.*, **23**, 1319–1328.
- Bothwell, A.L.M., Paskind, M., Reth, M., Imanishi-Kari, T., Rajewsky, K. and Baltimore, D. (1981) *Cell*, **24**, 625–637.
- Breitling, F., Dübel, S., Seehaus, T., Klewinghaus, I. and Little, M. (1991) *Gene*, **104**, 147–153.
- Brownstone, A., Mitchison, N.A. and Pitt-Rivers, R. (1966) *Immunology*, **10**, 465–481.
- Chaiken, I., Rosé, S. and Karlsson, R. (1992) *Anal. Biochem.*, **201**, 197–210.
- Chothia, C. and Lesk, A.M. (1987) *J. Mol. Biol.*, **196**, 901–917.
- Chothia, C. *et al.* (1989) *Nature*, **342**, 877–883.
- Chothia, C., Lesk, A.M., Gherardi, E., Tomlinson, I.M., Walter, G., Marks, J.D., Llewelyn, M.B. and Winter, G. (1992) *J. Mol. Biol.*, **227**, 799–817.
- Chuchana, P., Blancher, A., Brockly, F., Alexandre, D., Lefranc, G. and Lefranc, M.P. (1990) *Eur. J. Immunol.*, **20**, 1317–1325.
- Clackson, T., Hoogenboom, H.R., Griffiths, A.D. and Winter, G. (1991) *Nature*, **352**, 624–628.
- Cox, J.P.L., Tomlinson, I.M. and Winter, G. (1994) *Eur. J. Immunol.*, **24**, 827–836.
- Cumano, A. and Rajewsky, K. (1985) *Eur. J. Immunol.*, **15**, 512–520.
- Cumano, A. and Rajewsky, K. (1986) *EMBO J.*, **5**, 2459–2468.
- De Bellis, D. and Schwartz, I. (1990) *Nucleic Acids Res.*, **18**, 1311.
- Denzin, L.K. and Voss, E.W. (1992) *J. Biol. Chem.*, **267**, 8925–8931.
- Dower, W.J., Miller, J.F. and Ragsdale, C.W. (1988) *Nucleic Acids Res.*, **16**, 6127–6145.
- Eisen, H.N. (1964) *Methods Med. Res.*, **10**, 115–121.
- Foot, J. and Milstein, C. (1991) *Nature*, **352**, 530–532.
- Garrard, L.J., Yang, M., O'Connell, M.P., Kelley, R.F. and Henner, D.J. (1991) *BioTechnology*, **9**, 1373–1377.
- Gibson, T.J. (1984) *PhD thesis*, University of Cambridge, UK.
- Griffiths, G.M., Berek, C., Kaartinen, M. and Milstein, C. (1984) *Nature*, **312**, 271–275.
- Griffiths, A.D. *et al.* (1993) *EMBO J.*, **12**, 725–734.
- Güssow, D. and Clackson, T. (1989) *Nucleic Acids Res.*, **17**, 4000.
- Hawkins, R.E., Russell, S.J. and Winter, G. (1992) *J. Mol. Biol.*, **226**, 889–896.
- Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. and Stüber, D. (1988) *BioTechnology*, **6**, 1321–1325.
- Hoess, R.H., Ziese, M. and Sternberg, N. (1982) *Proc. Natl Acad. Sci. USA*, **79**, 3398–3402.
- Hoess, R.H., Wierzbicki, A. and Abremski, K. (1986) *Nucleic Acids Res.*, **14**, 2287–2300.
- Hoffmann, A. and Roeder, R.G. (1991) *Nucleic Acids Res.*, **19**, 6337–6338.
- Holliger, P., Prospero, T. and Winter, G. (1993) *Proc. Natl Acad. Sci. USA*, **90**, 6444–6448.
- Hoogenboom, H.R. and Winter, G. (1992) *J. Mol. Biol.*, **227**, 381–388.
- Hoogenboom, H.R., Griffiths, A.D., Johnson, K.S., Chiswell, D.J., Hudson, P. and Winter, G. (1991) *Nucleic Acids Res.*, **19**, 4133–4137.
- Horton, R.M., Hunt, H.D., Ho, S.N., Pullen, J.K. and Pease, L.R. (1989) *Gene*, **77**, 61–68.
- Huse, W.D., Sastry, L., Iverson, S.A., Kang, A.S., Alting, M.M., Burton, D.R., Benkovic, S.J. and Lerner, R.A. (1989) *Science*, **246**, 1275–1281.
- Johnsson, B., Löfås, S. and Lindqvist, G. (1991) *Anal. Biochem.*, **198**, 268–277.
- Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S. and Foeller, C. (1991) *Sequences of Immunological Interest*. 5th edn, US Dept of Health and Human Services, Bethesda, USA.
- Karlsson, R., Michaelsson, A. and Mattsson, L. (1991) *J. Immunol. Methods*, **145**, 229–240.
- Karlsson, R., Fägerstam, L., Nilhans, H. and Persson, B. (1993) *J. Immunol. Methods*, **166**, 75–84.
- Kranz, D.M. and Voss, E.W. (1981) *Mol. Immunol.*, **18**, 889–898.
- Kranz, D.M., Herron, J.N. and Voss, E.W. (1982) *J. Biol. Chem.*, **257**, 6987–6995.
- Laemmli, U.K. (1970) *Nature*, **227**, 680–685.
- Luciano, Valim, Y.M. and Lachmann, P.J. (1991) *Clin. Exp. Immunol.*, **84**, 1–8.
- Mäkelä, O., Kaartinen, M., Pelkonen, J.L.T. and Karjalainen, K.J. (1978) *J. Exp. Med.*, **148**, 1644–1660.
- Mariuzza, R. and Strand, M. (1981) *Mol. Immunol.*, **18**, 847–855.
- Marks, J.D., Hoogenboom, H.R., Bonner, T.P., McCafferty, J., Griffiths, A.D. and Winter, G. (1991) *J. Mol. Biol.*, **222**, 581–597.
- Marks, J.D., Hoogenboom, H.R., Griffiths, A.D. and Winter, G. (1992a) *J. Biol. Chem.*, **267**, 16007–16010.
- Marks, J.D., Griffiths, A.D., Malmqvist, M., Clackson, T., Bye, J.M. and Winter, G. (1992b) *BioTechnology*, **10**, 779–783.
- Marks, J.D., Ouwehand, W.H., Bye, J.M., Finnern, R., Gorick, B.D., Voak, D., Thorpe, S., Hughes-Jones, N.C. and Winter, G. (1993) *BioTechnology*, **11**, 1145–1149.
- McCafferty, J., Griffiths, A.D., Winter, G. and Chiswell, D.J. (1990) *Nature*, **348**, 552–554.
- Miller, J.H. (1972) *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.
- Munro, S. and Pelham, H.R.B. (1986) *Cell*, **46**, 291–300.
- Nissim, A., Hoogenboom, H.R., Tomlinson, I.M., Flynn, G., Midgley, C., Lane, D. and Winter, G. (1994) *EMBO J.*, **13**, 692–698.
- Nossal, G.J. (1993) *Ann. N.Y. Acad. Sci.*, **690**, 34–41.
- O'Shannessy, D.J. (1990) *Methods Enzymol.*, **184**, 162–166.
- O'Shannessy, D.J., Brigham-Burke, M. and Peck, K. (1992) *Anal. Biochem.*, **205**, 132–136.
- Perelson, A.S. and Oster, G.F. (1979) *J. Theor. Biol.*, **81**, 645–670.
- Rathjen, D.A., Furphy, L.J. and Aston, R. (1992) *Br. J. Cancer*, **65**, 852–856.
- Reinitz, D.M. and Voss, E.W. (1984) *Mol. Immunol.*, **21**, 775–784.
- Rosner, J.L. (1972) *Virology*, **48**, 679–689.
- Sambrook, J., Fritsch, E.F. and Maniatis, T. (1990) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.
- Schwartz, R.S. and Stollar, B.D. (1994) *Immunol. Today*, **15**, 27–32.
- Skerra, A., Dreher, M.L. and Winter, G. (1991) *Anal. Biochem.*, **196**, 151–155.
- Smith, G.P. (1985) *Science*, **228**, 1315–1317.
- Sternberg, N. and Hamilton, D. (1981) *J. Mol. Biol.*, **150**, 467–486.
- Tomlinson, I.M., Walter, G., Marks, J.D., Llewelyn, M.B. and Winter, G. (1992) *J. Mol. Biol.*, **227**, 776–798.
- Tomlinson, I.M., Cook, G.P., Carter, N.P., Elaszwarapu, R., Smith, S., Walter, G., Buluwela, L., Rabbits, T.H. and Winter, G. (1994) *Human Mol. Gen.*, **3**, 853–860.

- Vasicek,T.J. and Leder,P. (1990) *J. Exp. Med.*, **172**, 609–620.
- Vieira,J. and Messing,J. (1987) *Methods Enzymol.*, **153**, 3–11.
- Waterhouse,P., Griffiths,A.D., Johnson,K.S. and Winter,G. (1993) *Nucleic Acids Res.*, **21**, 2265–2266.
- Weber,P. and Hof,L. (1975) *Biochem. Biophys. Res. Commun.*, **65**, 1298–1302.
- Williams,S.C. and Winter,G. (1993) *Eur. J. Immunol.*, **23**, 1456–1461.
- Winter,G., Griffiths,A.D., Hawkins,R.E. and Hoogenboom,H.R. (1994) *Annu. Rev. Immunol.*, **12**, 433–455.
- Wu,T.T., Johnson,G. and Kabat,E.A. (1993) *Proteins*, **16**, 1–7.
- Yanisch-Perron,C., Vieira,J. and Messing,J. (1985) *Gene*, **33**, 103–119.
- Yarmolinsky,M.B., Hansen,E.B., Jafri,S. and Chatteraj,D.K. (1989) *J. Bacteriol.*, **171**, 4785–4791.

Received on March 2, 1994; revised on May 5, 1994